289 results on '"Francois Villinger"'
Search Results
2. Anti-human immunodeficiency virus-1 activity of MoMo30 protein isolated from the traditional African medicinal plant Momordica balsamina
- Author
-
Mahfuz Khan, Amad Diop, Erick Gbodossou, Peng Xiao, Morgan Coleman, Kenya De Barros, Hao Duong, Vincent C. Bond, Virginia Floyd, Kofi Kondwani, Valerie Montgomery Rice, Sandra Harris-Hooker, Francois Villinger, and Michael D. Powell
- Subjects
Infectious Diseases ,Virology - Abstract
Background Plants are used in traditional healing practices of many cultures worldwide. Momordica balsamina is a plant commonly used by traditional African healers as a part of a treatment for HIV/AIDS. It is typically given as a tea to patients with HIV/AIDS. Water-soluble extracts of this plant were found to contain anti-HIV activity. Methods We employed cell-based infectivity assays, surface plasmon resonance, and a molecular-cell model of the gp120-CD4 interaction to study the mechanism of action of the MoMo30-plant protein. Using Edman degradation results of the 15 N-terminal amino acids, we determined the gene sequence of the MoMo30-plant protein from an RNAseq library from total RNA extracted from Momordica balsamina. Results Here, we identify the active ingredient of water extracts of the leaves of Momordica balsamina as a 30 kDa protein we call MoMo30-plant. We have identified the gene for MoMo30 and found it is homologous to a group of plant lectins known as Hevamine A-like proteins. MoMo30-plant is distinct from other proteins previously reported agents from the Momordica species, such as ribosome-inactivating proteins such as MAP30 and Balsamin. MoMo30-plant binds to gp120 through its glycan groups and functions as a lectin or carbohydrate-binding agent (CBA). It inhibits HIV-1 at nanomolar levels and has minimal cellular toxicity at inhibitory levels. Conclusions CBAs like MoMo30 can bind to glycans on the surface of the enveloped glycoprotein of HIV (gp120) and block entry. Exposure to CBAs has two effects on the virus. First, it blocks infection of susceptible cells. Secondly, MoMo30 drives the selection of viruses with altered glycosylation patterns, potentially altering their immunogenicity. Such an agent could represent a change in the treatment strategy for HIV/AIDS that allows a rapid reduction in viral loads while selecting for an underglycosylated virus, potentially facilitating the host immune response.
- Published
- 2023
3. Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates
- Author
-
Lochana M. Seenappa, Aniela Jakubowski, Martin P. Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, Jane Fontenot, Francois Villinger, Lisa K. McNeil, and Peter C. DeMuth
- Subjects
Pharmacology ,Infectious Diseases ,Immunology ,Pharmacology (medical) - Abstract
Despite the success of currently authorized vaccines for the reduction of severe COVID-19 disease risk, rapidly emerging viral variants continue to drive pandemic waves of infection, resulting in numerous global public health challenges. Progress will depend on future advances in prophylactic vaccine activity, including advancement of candidates capable of generating more potent induction of cross-reactive T cells and durable cross-reactive antibody responses. Here we evaluated an Amphiphile (AMP) adjuvant, AMP-CpG, admixed with SARS-CoV-2 Spike receptor binding domain (RBD) immunogen, as a lymph node-targeted protein subunit vaccine (ELI-005) in mice and non-human primates (NHPs). AMP-mediated targeting of CpG DNA to draining lymph nodes resulted in comprehensive local immune activation characterized by extensive transcriptional reprogramming, inflammatory proteomic milieu, and activation of innate immune cells as key orchestrators of antigen-directed adaptive immunity. Prime-boost immunization with AMP-CpG in mice induced potent and durable T cell responses in multiple anatomical sites critical for prophylactic efficacy and prevention of severe disease. Long-lived memory responses were rapidly expanded upon re-exposure to antigen. In parallel, RBD-specific antibodies were long-lived, and exhibited cross-reactive recognition of variant RBD. AMP-CpG-adjuvanted prime-boost immunization in NHPs was safe and well tolerated, while promoting multi-cytokine-producing circulating T cell responses cross-reactive across variants of concern (VOC). Expansion of RBD-specific germinal center (GC) B cells in lymph nodes correlated to rapid seroconversion with variant-specific neutralizing antibody responses exceeding those measured in convalescent human plasma. These results demonstrate the promise of lymph-node adjuvant-targeting to coordinate innate immunity and generate robust adaptive responses critical for vaccine efficacy.
- Published
- 2022
4. Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues
- Author
-
Amarendra Pegu, Danijela Maric, Patrick J. Madden, Ann M. Carias, Jeffrey R Schneider, Francois Villinger, Gianguido C. Cianci, Thomas J. Hope, Ramon Lorenzo-Redondo, Ronald S. Veazey, Mariluz Araínga, and John R. Mascola
- Subjects
Immunology ,Simian Acquired Immunodeficiency Syndrome ,Human immunodeficiency virus (HIV) ,Physiology ,HIV Infections ,Stratified squamous epithelium ,HIV Antibodies ,Simian ,medicine.disease_cause ,Article ,Submucosa ,medicine ,Stratum corneum ,Animals ,Humans ,Immunology and Allergy ,Distribution (pharmacology) ,biology ,business.industry ,Vaginal mucosa ,Immunoglobulins, Intravenous ,biology.organism_classification ,Macaca mulatta ,medicine.anatomical_structure ,HIV-1 ,biology.protein ,Female ,Simian Immunodeficiency Virus ,Antibody ,business - Abstract
i.v. injected Abs have demonstrated protection against simian HIV infection in rhesus macaques, paving the way for the Antibody Mediated Prevention trial in which at-risk individuals for HIV received an i.v. infusion of the HIV broadly neutralizing Ab VRC01. However, the time needed for these Abs to fully distribute and elicit protection at mucosal sites is still unknown. In this study, we interrogate how long it takes for Abs to achieve peak anatomical levels at the vaginal surface following i.v. injection. Fluorescently labeled VRC01 and/or Gamunex-C were i.v. injected into 24 female rhesus macaques (Macaca mulatta) with vaginal tissues and plasma acquired up to 2 wk postinjection. We found that Ab delivery to the vaginal mucosa occurs in two phases. The first phase involves delivery to the submucosa, occurring within 24 h and persisting beyond 1 wk. The second phase is the delivery through the stratified squamous epithelium, needing ∼1 wk to saturate the stratum corneum. This study has important implications for the efficacy of immunoprophylaxis targeting pathogens at the mucosa.
- Published
- 2021
5. Identification of a Novel Anti-HIV-1 Protein from
- Author
-
Morgan I, Coleman, Mahfuz, Khan, Erick, Gbodossou, Amad, Diop, Kenya, DeBarros, Hao, Duong, Vincent C, Bond, Virginia, Floyd, Kofi, Kondwani, Valerie, Montgomery Rice, Francois, Villinger, and Michael D, Powell
- Subjects
Plant Extracts ,HIV Seropositivity ,HIV-1 ,Momordica ,HIV Infections ,Antiviral Agents - Abstract
Our lab investigates the anti-HIV-1 activity in
- Published
- 2022
6. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine
- Author
-
Prabhu S. Arunachalam, Yupeng Feng, Usama Ashraf, Mengyun Hu, Alexandra C. Walls, Venkata Viswanadh Edara, Veronika I. Zarnitsyna, Pyone Pyone Aye, Nadia Golden, Marcos C. Miranda, Kristyn W. M. Green, Breanna M. Threeton, Nicholas J. Maness, Brandon J. Beddingfield, Rudolf P. Bohm, Sarah E. Scheuermann, Kelly Goff, Jason Dufour, Kasi Russell-Lodrigue, Elizabeth Kepl, Brooke Fiala, Samuel Wrenn, Rashmi Ravichandran, Daniel Ellis, Lauren Carter, Kenneth Rogers, Lisa M. Shirreff, Douglas E. Ferrell, Nihar R. Deb Adhikary, Jane Fontenot, Holly L. Hammond, Matthew Frieman, Alba Grifoni, Alessandro Sette, Derek T. O’Hagan, Robbert Van Der Most, Rino Rappuoli, Francois Villinger, Harry Kleanthous, Jay Rappaport, Mehul S. Suthar, David Veesler, Taia T. Wang, Neil P. King, and Bali Pulendran
- Subjects
COVID-19 Vaccines ,Adjuvants, Immunologic ,SARS-CoV-2 ,Vaccines, Subunit ,Animals ,COVID-19 ,Humans ,Viral Vaccines ,General Medicine ,Antibodies, Viral ,Antibodies, Neutralizing - Abstract
Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from a study in nonhuman primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain (RBD-Wu) on the I53-50 nanoparticle adjuvanted with AS03, which was recently authorized for use in individuals 18 years or older. Vaccination induced neutralizing antibody (nAb) titers that were maintained at high concentrations for at least 1 year after two doses, with a pseudovirus nAb geometric mean titer (GMT) of 1978 and a live virus nAb GMT of 1331 against the ancestral strain but not against the Omicron BA.1 variant. However, a booster dose at 6 to 12 months with RBD-Wu or RBD-β (RBD from the Beta variant) displayed on I53-50 elicited high neutralizing titers against the ancestral and Omicron variants. In addition, we observed persistent neutralization titers against a panel of sarbecoviruses, including SARS-CoV. Furthermore, there were substantial and persistent memory T and B cell responses reactive to Beta and Omicron variants. Vaccination resulted in protection against Omicron infection in the lung and suppression of viral burden in the nares at 6 weeks after the final booster immunization. Even at 6 months after vaccination, we observed protection in the lung and rapid control of virus in the nares. These results highlight the durable and cross-protective immunity elicited by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine.
- Published
- 2022
- Full Text
- View/download PDF
7. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
- Author
-
Brittany L. Hartwell, Mariane B. Melo, Peng Xiao, Ashley A. Lemnios, Na Li, Jason Y.H. Chang, Jingyou Yu, Makda S. Gebre, Aiquan Chang, Laura Maiorino, Crystal Carter, Tyson J. Moyer, Neil C. Dalvie, Sergio A. Rodriguez-Aponte, Kristen A. Rodrigues, Murillo Silva, Heikyung Suh, Josetta Adams, Jane Fontenot, J. Christopher Love, Dan H. Barouch, Francois Villinger, Ruth M. Ruprecht, and Darrell J. Irvine
- Subjects
Mice, Inbred BALB C ,SARS-CoV-2 ,Vaccination ,COVID-19 ,HIV Infections ,General Medicine ,Antibodies, Viral ,Lipids ,Macaca mulatta ,Immunoglobulin A ,Mice ,Albumins ,Immunoglobulin G ,Animals ,Immunity, Mucosal ,Administration, Intranasal - Abstract
To combat the HIV epidemic and emerging threats such as SARS-CoV-2, immunization strategies are needed that elicit protection at mucosal portals of pathogen entry. Immunization directly through airway surfaces is effective in driving mucosal immunity, but poor vaccine uptake across the mucus and epithelial lining is a limitation. The major blood protein albumin is constitutively transcytosed bidirectionally across the airway epithelium through interactions with neonatal Fc receptors (FcRn). Exploiting this biology, here, we demonstrate a strategy of “albumin hitchhiking” to promote mucosal immunity using an intranasal vaccine consisting of protein immunogens modified with an amphiphilic albumin-binding polymer-lipid tail, forming amph-proteins. Amph-proteins persisted in the nasal mucosa of mice and nonhuman primates and exhibited increased uptake into the tissue in an FcRn-dependent manner, leading to enhanced germinal center responses in nasal-associated lymphoid tissue. Intranasal immunization with amph-conjugated HIV Env gp120 or SARS-CoV-2 receptor binding domain (RBD) proteins elicited 100- to 1000-fold higher antigen-specific IgG and IgA titers in the serum, upper and lower respiratory mucosa, and distal genitourinary mucosae of mice compared to unmodified protein. Amph-RBD immunization induced high titers of SARS-CoV-2–neutralizing antibodies in serum, nasal washes, and bronchoalveolar lavage. Furthermore, intranasal amph-protein immunization in rhesus macaques elicited 10-fold higher antigen-specific IgG and IgA responses in the serum and nasal mucosa compared to unmodified protein, supporting the translational potential of this approach. These results suggest that using amph-protein vaccines to deliver antigen across mucosal epithelia is a promising strategy to promote mucosal immunity against HIV, SARS-CoV-2, and other infectious diseases.
- Published
- 2022
8. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- Author
-
Shankar Subramaniam, David Veesler, Lauren Carter, David Novack, Claire Sydeman, Jane Fontenot, Douglas E. Ferrell, Galit Alter, Robbert van der Most, Robert L. Coffman, Elizabeth Kepl, Mary Jane Navarro, Alexander G. White, Ching-Lin Hsieh, Kenneth S. Plante, Francois Villinger, Katharina Röltgen, Prabhu S. Arunachalam, Alexandra C. Walls, Jason S. McLellan, Lisa Shirreff, Rino Rappuoli, Sally Shin, Venkata Viswanadh Edara, Jessica A. Plante, Brooke Fiala, Stephanie Fischinger, Chunfeng Li, Caroline Atyeo, Matthew J. Gorman, Chad J. Roy, Scott D. Boyd, Bali Pulendran, Kasi E. Russell-Lodrigue, Skye Spencer, Xiaoying Shen, Shakti Gupta, Derek T. O'Hagan, Pyone P. Aye, Meera Trisal, Neil P. King, JoAnne L. Flynn, Nadia A. Golden, Marcos C. Miranda, Michael E. P. Murphy, John C. Kraft, Mehul S. Suthar, Lilin Lai, Jason Dufour, Rudolph Bohm, Deleah Pettie, Lara A. Doyle-Meyers, David C. Montefiori, Christopher Monjure, Kenneth A. Rogers, Samuel Wrenn, Harry Kleanthous, Nicholas J. Maness, Jay Rappaport, Alex Lee Zhu, and Natalie Brunette
- Subjects
0301 basic medicine ,Multidisciplinary ,Immunogen ,Alum ,medicine.medical_treatment ,Biology ,Virology ,Neutralization ,Vaccination ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Immunization ,chemistry ,Immunity ,medicine ,030212 general & internal medicine ,AS03 ,Adjuvant - Abstract
The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses and protection against SARS-CoV-2 in rhesus macaques. We evaluated five adjuvants including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an α-tocopherol-containing oil-in-water emulsion; AS37, a Toll-like receptor 7 (TLR7) agonist adsorbed to alum; CpG1018-alum, a TLR9 agonist formulated in alum; and alum. RBD-NP immunization with AS03, CpG1018-alum, AS37 or alum induced substantial neutralizing-antibody and CD4 T cell responses, and conferred protection against SARS-CoV-2 infection in the pharynges, nares and bronchoalveolar lavage. The neutralizing-antibody response to live virus was maintained up to 180 days after vaccination with RBD-NP in AS03 (RBD-NP-AS03), and correlated with protection from infection. RBD-NP immunization cross-neutralized the B.1.1.7 SARS-CoV-2 variant efficiently but showed a reduced response against the B.1.351 variant. RBD-NP-AS03 produced a 4.5-fold reduction in neutralization of B.1.351 whereas the group immunized with RBD-NP-AS37 produced a 16-fold reduction in neutralization of B.1.351, suggesting differences in the breadth of the neutralizing-antibody response induced by these adjuvants. Furthermore, RBD-NP-AS03 was as immunogenic as a prefusion-stabilized spike immunogen (HexaPro) with AS03 adjuvant. These data highlight the efficacy of the adjuvanted RBD-NP vaccine in promoting protective immunity against SARS-CoV-2 and have led to phase I/II clinical trials of this vaccine (NCT04742738 and NCT04750343).
- Published
- 2021
9. Programming the lymph node immune response with Amphiphile-CpG induces potent cellular and humoral immunity following COVID-19 subunit vaccination in mice and non-human primates
- Author
-
Lochana M. Seenappa, Aniela Jakubowski, Martin P. Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, Jane Fontenot, Francois Villinger, Lisa K. McNeil, and Peter C. DeMuth
- Abstract
Despite the success of currently authorized vaccines for the reduction of severe COVID-19 disease risk, rapidly emerging viral variants continue to drive pandemic waves of infection, resulting in numerous global public health challenges. Progress will depend on future advances in prophylactic vaccine activity, including advancement of candidates capable of generating more potent induction of cross-reactive T cells and durable cross-reactive antibody responses. Here we evaluated an Amphiphile (AMP) adjuvant, AMP-CpG, admixed with SARS-CoV-2 Spike receptor binding domain (RBD) immunogen, as a lymph node-targeted protein subunit vaccine (ELI-005) in mice and non-human primates (NHPs). AMP-mediated targeting of CpG DNA to draining lymph nodes resulted in comprehensive local immune activation characterized by extensive transcriptional reprogramming, inflammatory proteomic milieu, and activation of innate immune cells as key orchestrators of antigen-directed adaptive immunity. Prime-boost immunization with AMP-CpG in mice induced potent and durable T cell responses in multiple anatomical sites critical for prophylactic efficacy and prevention of severe disease. Long-lived memory responses were rapidly expanded upon re-exposure to antigen. In parallel, RBD-specific antibodies were long-lived, and exhibited cross-reactive recognition of variant RBD. AMP-CpG-adjuvanted prime-boost immunization in NHPs was safe and well tolerated, while promoting multi-cytokine-producing circulating T cell responses cross-reactive across variants of concern (VOC). Expansion of RBD-specific germinal center (GC) B cells in lymph nodes correlated to rapid seroconversion with variant-specific neutralizing antibody responses exceeding those measured in convalescent human plasma. These results demonstrate the promise of lymph-node adjuvant-targeting to coordinate innate immunity and generate robust adaptive responses critical for vaccine efficacy.
- Published
- 2022
10. Hypo-osmolar rectal douche tenofovir formulation prevents simian/human immunodeficiency virus acquisition in macaques
- Author
-
Peng Xiao, Sanjeev Gumber, Mark A. Marzinke, Thuy Hoang, Rohan Myers, Abhijit A. Date, Justin Hanes, Laura M. Ensign, Lin Wang, Lisa C. Rohan, Richard Cone, Edward J. Fuchs, Craig W. Hendrix, and Francois Villinger
- Subjects
Male ,Sexual and Gender Minorities ,Humans ,Animals ,Macaca ,HIV ,HIV Infections ,General Medicine ,Homosexuality, Male ,Tenofovir - Abstract
In spite of the rollout of oral pre-exposure prophylaxis (PrEP), the rate of new HIV infections remains a major health crisis. In the United States, new infections occur predominantly in men having sex with men (MSM) in rural settings where access to PrEP can be limited. As an alternative congruent with MSM sexual behavior, we have optimized and tested tenofovir (TFV) and analog-based iso-osmolar and hypo-osmolar (HOsm) rectal douches for efficacy against rectal simian/human immunodeficiency virus (SHIV) infection of macaques. Single TFV HOsm high-dose douches achieved peak plasma TFV levels similar to daily oral PrEP, while other formulations yielded lower concentrations. Rectal tissue TFV-diphosphate (TFV-DP) concentrations at the portal of virus entry, however, were markedly higher after HOsm douching than daily oral PrEP. Repeated douches led to significantly higher plasma TFV and higher TFV-DP concentrations in rectal tissue at 24 hours compared with single douches, without detectable mucosal or systemic toxicity. Using stringent repeated intrarectal SHIV exposures, single HOsm high-dose douches delivered greater protection from virus acquisition for more than 24 hours compared with oral PrEP. Our results demonstrate a rapid delivery of protective TFV doses to the rectal portal of virus entry as a potential low-cost and safe PrEP alternative.
- Published
- 2022
11. Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine
- Author
-
Prabhu S. Arunachalam, Yupeng Feng, Usama Ashraf, Mengyun Hu, Venkata Viswanadh Edara, Veronika I. Zarnitsyna, Pyone Pyone Aye, Nadia Golden, Kristyn W. M. Green, Breanna M. Threeton, Nicholas J. Maness, Brandon J. Beddingfield, Rudolf P. Bohm, Jason Dufour, Kasi Russell-Lodrigue, Marcos C. Miranda, Alexandra C. Walls, Kenneth Rogers, Lisa Shirreff, Douglas E Ferrell, Nihar R. Deb Adhikary, Jane Fontenot, Alba Grifoni, Alessandro Sette, Derek T. O’Hagan, Robbert Van Der Most, Rino Rappuoli, Francois Villinger, Harry Kleanthous, Jay Rappaport, Mehul S. Suthar, David Veesler, Taia T. Wang, Neil P. King, and Bali Pulendran
- Abstract
SummaryDespite the remarkable efficacy of COVID-19 vaccines, waning immunity, and the emergence of SARS-CoV-2 variants such as Omicron represents a major global health challenge. Here we present data from a study in non-human primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine, consisting of RBD (receptor binding domain) on the I53-50 nanoparticle, adjuvanted with AS03, currently in Phase 3 clinical trial (NCT05007951). Vaccination induced robust neutralizing antibody (nAb) titers that were maintained at high levels for at least one year after two doses (Pseudovirus nAb GMT: 2207, Live-virus nAb GMT: 1964) against the ancestral strain, but not against Omicron. However, a booster dose at 6-12 months with RBD-Wu or RBD-β (RBD from the Beta variant) displayed on I53-50 elicited equivalent and remarkably high neutralizing titers against the ancestral as well as the Omicron variant. Furthermore, there were substantial and persistent memory T and B cell responses reactive to Beta and Omicron variants. Importantly, vaccination resulted in protection against Omicron infection in the lung (no detectable virus in any animal) and profound suppression of viral burden in the nares (median peak viral load of 7567 as opposed to 1.3×107 copies in unvaccinated animals) at 6 weeks post final booster. Even at 6 months post vaccination, there was significant protection in the lung (with 7 out of 11 animals showing no viral load, 3 out of 11 animals showing ~20-fold lower viral load than unvaccinated controls) and rapid control of virus in the nares. These results highlight the durable cross-protective immunity elicited by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine platform.
- Published
- 2022
12. Cytokine Adjuvants IL-7 and IL-15 Improve Humoral Responses of a SHIV LentiDNA Vaccine in Animal Models
- Author
-
Jean Gagnon, Yahia Chebloune, Alice Mac Donald, Francois Villinger, Deepanwita Bose, Aditi Kandlur, Laury-Anne LEROY, and Peng Xiao
- Subjects
Pharmacology ,Infectious Diseases ,animal diseases ,Drug Discovery ,Immunology ,Pharmacology (medical) ,HIV-1 ,DNA vaccine ,CAEV LTR ,LentiDNA ,SHIV ,IL-7 ,IL-15 ,Rhesus macaques - Abstract
HIV-1 remains a major public health issue worldwide in spite of efficacious antiviral therapies, but with no cure or preventive vaccine. The latter has been very challenging, as virus infection is associated with numerous escape mechanisms from host specific immunity and the correlates of protection remain incompletely understood. We have developed an innovative vaccine strategy, inspired by the efficacy of live-attenuated virus, but with the safety of a DNA vaccine, to confer both cellular and humoral responses. The CAL-SHIV-IN− lentiDNA vaccine comprises the backbone of the pathogenic SHIVKU2 genome, able to mimic the early phase of viral infection, but with a deleted integrase gene to ensure safety precluding integration within the host genome. This vaccine prototype, constitutively expressing viral antigen under the CAEV LTR promoter, elicited a variety of vaccine-specific, persistent CD4 and CD8 T cells against SIV-Gag and Nef up to 80 weeks post-immunization in cynomolgus macaques. Furthermore, these specific responses led to antiviral control of the pathogenic SIVmac251. To further improve the efficacy of this vaccine, we incorporated the IL-7 or IL-15 genes into the CAL-SHIV-IN− plasmid DNA in efforts to increase the pool of vaccine-specific memory T cells. In this study, we examined the immunogenicity of the two co-injected lentiDNA vaccines CAL-SHIV-IN− IRES IL-7 and CAL-SHIV-IN− IRES IL-15 in BALB/cJ mice and rhesus macaques and compared the immune responses with those generated by the parental vaccine CAL-SHIV-IN−. This co-immunization elicited potent vaccine-specific CD4 and CD8 T cells both in mice and rhesus macaques. Antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies were detected up to 40 weeks post-immunization in both plasma and mucosal compartments of rhesus macaques and were enhanced by the cytokines.
- Published
- 2022
- Full Text
- View/download PDF
13. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques
- Author
-
Patrick Madden, Yanique Thomas, Robert Blair, Sadia Samer, Mark Doyle, Cecily Midkiff, Lara Doyle-Meyers, Mark Becker, Shoaib Arif, Michael McRaven, Lacy Simons, Ann Carias, Elena Martinelli, Ramon Lorenzo-Redondo, Judd Hultquist, Francois Villinger, Ronald Veazey, and Thomas Hope
- Subjects
skin and connective tissue diseases - Abstract
The systemic nature of SARS-CoV-2 infection is highly recognized, but poorly characterized. A non-invasive and unbiased method is needed to clarify whole body spatiotemporal dynamics of SARS-CoV-2 infection after transmission. We recently developed a probe based on the anti-SARS-CoV-2 spike antibody CR3022 to study SARS-CoV-2 pathogenesis in vivo. Herein, we describe its use in immunoPET to investigate SARS-CoV-2 infection of three rhesus macaques. Using PET/CT imaging of macaques at different times post-SARS-CoV-2 inoculation, we track the 64Cu-labelled CR3022-F(ab’)2 probe targeting the spike protein of SARS-CoV-2 to study the dynamics of infection within the respiratory tract and uncover novel sites of infection. Using this method, we uncovered differences in lung pathology between infection with the WA1 isolate and the delta variant, which were readily corroborated through computed tomography scans. The 64Cu-CR3022-probe also demonstrated dynamic changes occurring between 1- and 2-weeks post-infection. Remarkably, a robust signal was seen in the male genital tract (MGT) of all three animals studied. Infection of the MGT was validated by immunofluorescence imaging of infected cells in the testicular and penile tissue and severe pathology was observed in the testes of one animal at 2-weeks post-infection. The results presented here underscore the utility of using immunoPET to study the dynamics of SARS-CoV-2 infection to understand its pathogenicity and discover new anatomical sites of viral replication. We provide direct evidence for SARS-CoV-2 infection of the MGT in rhesus macaques revealing the possible pathologic outcomes of viral replication at these sites.Graphic AbstractPET/CT detected SARS-CoV-2 infection of 4 different tissues in the male genital tract illuminates the cause of COVID-19 clinical sequalae of male sexual health and fertility Figure 1.Diagram shows schematic illustration of the male genital tract of the rhesus macaque. Virus icon shows sites of SARS-CoV-2 PET signal. Text highlighting the clinical sequalae associated with each sight of infection is shown in text adjacent to each infection site.
- Published
- 2022
14. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
- Author
-
Alexandra C. Walls, Laura A. VanBlargan, Kai Wu, Angela Choi, Mary Jane Navarro, Diana Lee, Laura Avena, Daniela Montes Berrueta, Minh N. Pham, Sayda Elbashir, Marcos C. Miranda, Elizabeth Kepl, Max Johnson, Alyssa Blackstone, Kaitlin Sprouse, Brooke Fiala, Megan A. O’Connor, Natalie Brunette, Prabhu S. Arunachalam, Lisa Shirreff, Kenneth Rogers, Lauren Carter, Deborah H. Fuller, Francois Villinger, Bali Pulendran, Michael S. Diamond, Darin K. Edwards, Neil P. King, and David Veesler
- Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOC) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOC. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses against VOC, as compared to non-human primates or humans, suggesting caution should be exercised when interpreting data for this animal model.
- Published
- 2022
15. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
- Author
-
Alexandra C. Walls, Laura A. VanBlargan, Kai Wu, Angela Choi, Mary Jane Navarro, Diana Lee, Laura Avena, Daniela Montes Berrueta, Minh N. Pham, Sayda Elbashir, John C. Kraft, Marcos C. Miranda, Elizabeth Kepl, Max Johnson, Alyssa Blackstone, Kaitlin Sprouse, Brooke Fiala, Megan A. O’Connor, Natalie Brunette, Prabhu S. Arunachalam, Lisa Shirreff, Kenneth Rogers, Lauren Carter, Deborah H. Fuller, Francois Villinger, Bali Pulendran, Michael S. Diamond, Darin K. Edwards, Neil P. King, and David Veesler
- Subjects
Primates ,Mice ,Mice, Inbred BALB C ,SARS-CoV-2 ,Spike Glycoprotein, Coronavirus ,Animals ,COVID-19 ,Humans ,Viral Vaccines ,Antibodies, Viral ,Antibodies, Neutralizing ,General Biochemistry, Genetics and Molecular Biology - Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOCs) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOCs. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses elicited by various vaccine platforms against VOCs, compared with non-human primates or humans, suggesting caution should be exercised when interpreting data obtained with this animal model.
- Published
- 2022
16. Protective Immune Responses Elicited by Deglycosylated Live-Attenuated Simian Immunodeficiency Virus Vaccine Are Associated with IL-15 Effector Functions
- Author
-
Aftab A. Ansari, Hirotaka Sato, Emi E. Nakayama, Francois Villinger, Yohei Saito, Nursarat Ahmed, Tatsuo Shioda, Tomotaka Okamura, Kazuyasu Mori, Masayuki Fujino, Chie Sugimoto, Kouji Matsushima, Ken-Ichi Hanaki, and Satoru Watanabe
- Subjects
Innate immune system ,Immunology ,Heterologous ,Biology ,Simian immunodeficiency virus ,medicine.disease_cause ,Vaccination ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Viral replication ,Interleukin 15 ,medicine ,Immunology and Allergy ,CD8 ,030215 immunology - Abstract
Deglycosylated, live-attenuated SIV vaccines elicited protective immune responses against heterologous SIVsmE543-3, which differs from the vaccine strain SIVmac239 to levels similar to those across HIV-1 clades. Two thirds of the vaccinees contained the chronic SIVsmE543-3 infection (controllers), whereas one third did not (noncontrollers). In this study, we investigated immune correlates of heterologous challenge control in rhesus macaques of Burmese origin. Because depletion of CD8+ cells in the controllers by administration of anti-CD8α Ab abrogated the control of viral replication, CD8+ cells were required for the protective immune response. However, classical SIV-specific CD8+ T cells did not account for the protective immune response in all controllers. Instead, IL-15–responding CD8α+ cells, including CD8+ T and NK cells, were significantly higher in the controllers than those in the noncontrollers, before and after vaccination with deglycosylated SIV. It is well established that IL-15 signal transduction occurs through “trans-presentation” in which IL-15 complexed with IL-15Rα on monocytes, macrophages, and dendritic cells binds to IL-15 Rβ/γ expressed on CD8+ T and NK cells. Accordingly, levels of IL-15 stimulation were strongly affected by the depletion of monocytes from PBMCs, implying key roles of innate immune cells. These results suggest that intrinsic IL-15 responsiveness may dictate the outcome of protective responses and may lead to optimized formulations of future broadly protective HIV vaccines.
- Published
- 2020
17. Idiopathic chronic diarrhea associated with dysbiosis in a captive cynomolgus macaque ( Macaca fascicularis )
- Author
-
Eun-Ha Hwang, Hwal-Yong Lee, Seung Ho Baek, Yeonghoon Son, Jung Joo Hong, Kyung Seob Lim, Green Kim, Francois Villinger, Hanseul Oh, Kang Jin Jeong, Young-Hyun Kim, Philyong Kang, and Bonsang Koo
- Subjects
Diarrhea ,040301 veterinary sciences ,Physiology ,Cynomolgus macaque ,Inflammatory bowel disease ,0403 veterinary science ,Chronic diarrhea ,Animals ,Medicine ,0501 psychology and cognitive sciences ,Captive bred ,050102 behavioral science & comparative psychology ,Microbiome ,Unusual case ,General Veterinary ,business.industry ,Monkey Diseases ,05 social sciences ,04 agricultural and veterinary sciences ,medicine.disease ,Macaca fascicularis ,Chronic Disease ,Etiology ,Dysbiosis ,Female ,Animal Science and Zoology ,business - Abstract
Chronic inflammatory enteric diseases occur commonly in humans and animals, especially in captive bred macaques. However, information about the etiology of idiopathic chronic inflammatory diarrhea in cynomolgus monkeys is limited. In this paper, we reported the unusual case of idiopathic chronic diarrhea in a captive cynomolgus monkey based on microbial, imaging, and microbiome examinations.
- Published
- 2019
18. Tuberculosis detection in nonhuman primates is enhanced by using testing algorithms that include an interferon-γ release assay
- Author
-
Suchinda Malivijitnond, Amanda Carpenter, Jeffrey A. Roberts, Saradee Warit, Francois Villinger, Kamm Prongay, Dana L. Hasselschwert, Taratorn Kemthong, Peter B. Nham, JoAnn L. Yee, Kenneth A. Rogers, Koen K. A. Van Rompay, Alexandra N Jay, Bryson M. Halley, and Suthirote Meesawat
- Subjects
Primates ,Tuberculosis ,General Veterinary ,biology ,Outbreak ,Tuberculin ,General Medicine ,Disease ,biology.organism_classification ,medicine.disease ,Article ,Antigen ,Mycobacterium tuberculosis complex ,Humoral immunity ,medicine ,Animals ,Clinical significance ,Algorithm ,Algorithms ,Interferon-gamma Release Tests - Abstract
OBJECTIVE To develop a testing algorithm that incorporates multiple assays to evaluate host cellular and humoral immunity and antigen detection concerning Mycobacterium tuberculosis complex (MTBC) infection in captive nonhuman primates. ANIMALS Cohorts of captive-bred and wild-caught macaques from 5 different geographic regions. PROCEDURES Macaques were tested for MTBC infection by use of a γ interferon tuberculosis (GIFT) assay, an interferon-γ release assay, and other assays. In the first 2 cohorts (n = 15 and 181), initial validation of the GIFT assay was performed by use of experimentally infected and unexposed control macaques. In the next 3 cohorts (n = 59, 42, and 11), results were obtained for opportunistically collected samples from macaques exposed during spontaneous outbreaks. RESULTS Sensitivity and specificity of the GIFT assay in the control cohorts were 100% and 97%, respectively, and were variable but enhanced by incorporating results from multiple assays in spontaneous outbreaks. CLINICAL RELEVANCE The detection and management of MTBC infection in captive nonhuman primate populations is an ongoing challenge, especially with animal imports and transfers. Despite standardized practices of initial quarantine with regular intradermal tuberculin skin testing, spontaneous outbreaks continue to be reported. Since infection encompasses a range of disease manifestations over time, a testing algorithm that incorporates multiple assays, such as the GIFT assay, to evaluate host cellular and humoral immunity in addition to agent detection is needed. Testing a combination of samples from controlled studies and spontaneous outbreaks of MTBC infection in nonhuman primates would advance the development and validation of a functional algorithm that incorporates promising tools such as the GIFT assay.
- Published
- 2021
19. IL-21 enhances influenza vaccine responses in aged macaques with suppressed SIV infection
- Author
-
Constantinos Petrovas, Alexander Kizhner, Francois Villinger, Daniel Kvistad, Rajendra Pahwa, Savita Pahwa, Tirupataiah Sirupangi, and Suresh Pallikkuth
- Subjects
Influenza vaccine ,T cell ,Adaptive immunity ,Population ,Simian Acquired Immunodeficiency Syndrome ,medicine.disease_cause ,Virus ,AIDS/HIV ,TIGIT ,medicine ,Animals ,education ,Vaccines ,education.field_of_study ,business.industry ,Interleukins ,Germinal center ,General Medicine ,Simian immunodeficiency virus ,Acquired immune system ,Macaca mulatta ,Influenza ,medicine.anatomical_structure ,Influenza Vaccines ,Immunology ,Immunotherapy ,business ,Research Article - Abstract
Natural aging and human immunodeficiency virus (HIV) infection are associated with chronic low-grade systemic inflammation, immune senescence, and impaired antibody (Ab) responses to vaccines such as influenza (flu). We investigated the role of Interleukin (IL)-21, a CD4 T follicular helper cells (Tfh) regulator, on flu vaccine Ab response in non-human primates (NHPs) in the context of age and controlled simian immunodeficiency virus (SIV) mac239 infection. Three doses of the flu vaccine with or without IL-21-IgFc were administered at 3-month intervals in aged SIV+ NHPs following virus suppression with anti-retroviral therapy. IL-21 treated animals demonstrated higher day 14 post-boost Ab responses which associated with expanded CD4+ T CM cells and peripheral (p) Tfh expressing T cell immunoreceptor with Ig and ITIM domains (TIGIT), expanded activated memory B cells and contracted CD11b+ monocytes. Draining lymph node (LN) tissue from IL-21 treated animals revealed direct association between LN follicle Tfh density and frequency of circulating TIGIT+ pTfh cells. We conclude that IL-21 enhances flu vaccine-induced Ab responses in SIV+ aged RM acting as an adjuvant modulating LN germinal center activity. Strategies to supplement IL-21 in aging could be a valuable addition in the toolbox for improving vaccine responses in an aging HIV+ population.
- Published
- 2021
20. Abstract A021: Clinical and molecular characterization of naturally-occurring colorectal cancer in rhesus macaques reveals mismatch repair deficiency driven by epigenetic silencing of MLH1
- Author
-
Simon Deycmar, Brendan Johnson, Karina Ray, David Caudell Caudell, John Olson, Greg Dugan, W. Shane Sills, Declan Ryan, Christopher Whitlow, Kiran K. Solingapuram Sai, Betsy Ferguson, Benjamin Bimber, Cassandra Cullin, Brandy Dozier, Emily Romero, Francois Villinger, Armando Burgos, Jeff Chou, Bruno Gomes, Michael Hettich, Maurizio Ceppi, Jehad Charo, and J. Mark Cline
- Subjects
Cancer Research ,Oncology - Abstract
Naturally occurring colorectal cancers (CRC) in rhesus macaques share many features with their human counterparts and emerge at similar life stages as in human patients, but the carcinogenesis and molecular background remain elusive, limiting the value of the model for human disease and cancer therapy. In order to better understand this naturally occurring model, we established a diagnostic and staging pipeline including imaging (18F-FDG PET, plain and contrast-enhanced CT), histopathology, and clinical assessments. We observed cancer symptoms and co-morbidities in our cohort (n=16, all Indian-origin, 11 females, mean age at arrival 20.2y) such as hypoalbuminemia, fecal occult blood, and microcytic anemia, as frequently described in human CRC patients. Pathologically, all cancers were right-sided, involving the proximal colon and/or ileocecocolic junction, and most were densely fibrotic, restricting the colonic lumen. Most cancers appeared with glandular morphology and some (18.8%) had mucinous components. Immunohistochemistry revealed loss of MLH1 and PMS2 in 100% of investigated CRCs, indicating mismatch repair deficiency which furthermore resulted in microsatellite instability (PCR & fragment analysis). Whole exome sequencing revealed the close genetic relatedness to human CRCs, particularly exemplified by mutations affecting KRAS (37.5%, e.g., p.G12D), APC (31.3%), TP53 (18.8%, e.g. p.R175H), ARID1A (56.3%), and ALK (43.8%), as similarly annotated in the human COSMIC database. Nonetheless, somatic mutations do not explain the loss of MLH1 in the entire CRC cohort. Transcriptomics on the other hand revealed the transcriptional suppression of MLH1 but not MSH2, MSH6, or PMS2 in rhesus CRC in comparison to adjacent healthy colon. Moreover, comparison of differentially expressed gene sets of rhesus CRC with a human annotated database (IPA) confirmed the disease similarities observed clinically, genetically, and histopathologically. Subsequently, we investigated DNA methylation of the promoter region of MLH1 and retranslated markers for the CpG island methylator phenotype (CIMP) as described in human CRC. While only 56.3% of CRCs were considered CIMP positive (≥3/5 markers hypermethylated), 100% of investigated CRCs exhibited MLH1 promoter hypermethylation. As a result, epigenetic silencing is suggested to suppress MLH1 transcription, cause the loss of MLH1 protein, and drive mismatch repair deficiency and genomic instability in naturally occurring CRC in rhesus macaques. We therefore consider spontaneous, uninduced CRC in rhesus macaques, their treatment-naïve nature, and their unaltered immune competence an outstanding model for human disease and in particular for human cancer immunotherapy. Citation Format: Simon Deycmar, Brendan Johnson, Karina Ray, David Caudell Caudell, John Olson, Greg Dugan, W. Shane Sills, Declan Ryan, Christopher Whitlow, Kiran K. Solingapuram Sai, Betsy Ferguson, Benjamin Bimber, Cassandra Cullin, Brandy Dozier, Emily Romero, Francois Villinger, Armando Burgos, Jeff Chou, Bruno Gomes, Michael Hettich, Maurizio Ceppi, Jehad Charo, J. Mark Cline. Clinical and molecular characterization of naturally-occurring colorectal cancer in rhesus macaques reveals mismatch repair deficiency driven by epigenetic silencing of MLH1 [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1):Abstract nr A021.
- Published
- 2022
21. Identification of a Novel Anti-HIV-1 Protein from Momordica balsamina Leaf Extract
- Author
-
Morgan I. Coleman, Mahfuz Khan, Erick Gbodossou, Amad Diop, Kenya DeBarros, Hao Duong, Vincent C. Bond, Virginia Floyd, Kofi Kondwani, Valerie Montgomery Rice, Francois Villinger, and Michael D. Powell
- Subjects
Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,HIV-1 ,MoMo30 ,fusion inhibitor ,extract ,antiviral ,antiviral protein ,antiviral plant - Abstract
Our lab investigates the anti-HIV-1 activity in Momordica balsamina (M. balsamina) leaf extract. Traditional Senegalese healers have used M. balsamina leaf extract as a part of a plant-based treatment for HIV/AIDS infections. Our overall goal is to define and validate the scientific basis for using M. balsamina leaf extract as a part of the traditional Senegalese treatment. As an initial characterization of this extract, we used activity-guided fractionation to determine the active ingredient’s solubility and relative size. We found that M. balsamina leaf extract inhibits HIV-1 infection by >50% at concentrations of 0.02 mg/mL and above and is not toxic over its inhibitory range (0–0.5 mg/mL). We observed significantly more antiviral activity in direct water and acetonitrile extractions (p ≤ 0.05). We also observed significantly more antiviral activity in the aqueous phases of ethyl acetate, chloroform, and diethyl ether extractions (p ≤ 0.05). Though most of the antiviral activity partitioned into the aqueous layers, some antiviral activity was present in the organic layers. We show that the active agent in the plant extracts is at least 30 kD in size. Significantly more antiviral activity was retained in 3, 10, and 30 kD molecular weight cutoff filters (p ≤ 0.05). In contrast, most of the antiviral activity passed through the 100 kD filter (p ≤ 0.05). Because the active anti-HIV-1 agent presented as a large, amphiphilic molecule we ran the purified extract on an SDS-page gel. We show that the anti-HIV-1 activity in the leaf extracts is attributed to a 30 kDa protein we call MoMo30. This article describes how MoMo30 was determined to be responsible for its anti-HIV-1 activity.
- Published
- 2022
22. Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung
- Author
-
Laura Rotolo, Daryll Vanover, Nicholas C. Bruno, Hannah E. Peck, Chiara Zurla, Jackelyn Murray, Richard K. Noel, Laura O’Farrell, Mariluz Araínga, Nichole Orr-Burks, Jae Yeon Joo, Lorena C. S. Chaves, Younghun Jung, Jared Beyersdorf, Sanjeev Gumber, Ricardo Guerrero-Ferreira, Santiago Cornejo, Merrilee Thoresen, Alicia K. Olivier, Katie M. Kuo, James C. Gumbart, Amelia R. Woolums, Francois Villinger, Eric R. Lafontaine, Robert J. Hogan, M. G. Finn, and Philip J. Santangelo
- Subjects
Mechanics of Materials ,Mechanical Engineering ,General Materials Science ,General Chemistry ,Condensed Matter Physics - Abstract
Messenger RNA has now been used to vaccinate millions of people. However, the diversity of pulmonary pathologies, including infections, genetic disorders, asthma and others, reveals the lung as an important organ to directly target for future RNA therapeutics and preventatives. Here we report the screening of 166 polymeric nanoparticle formulations for functional delivery to the lungs, obtained from a combinatorial synthesis approach combined with a low-dead-volume nose-only inhalation system for mice. We identify P76, a poly-β-amino-thio-ester polymer, that exhibits increased expression over formulations lacking the thiol component, delivery to different animal species with varying RNA cargos and low toxicity. P76 allows for dose sparing when delivering an mRNA-expressed Cas13a-mediated treatment in a SARS-CoV-2 challenge model, resulting in similar efficacy to a 20-fold higher dose of a neutralizing antibody. Overall, the combinatorial synthesis approach allowed for the discovery of promising polymeric formulations for future RNA pharmaceutical development for the lungs.
- Published
- 2021
23. Evaluation of a New Viral Vaccine Vector in Mice and Rhesus Macaques: J Paramyxovirus Expressing Hemagglutinin of Influenza A Virus H5N1
- Author
-
Peng Xiao, Biao He, Francois Villinger, Mathew Abraham, S. Mark Tompkins, Ashley C. Beavis, Cheryl A Jones, and Zhuo Li
- Subjects
Male ,H5N1 vaccine ,Immunology ,Hemagglutinin (influenza) ,Hemagglutinin Glycoproteins, Influenza Virus ,medicine.disease_cause ,Microbiology ,Virus ,Cell Line ,Mice ,Dogs ,Orthomyxoviridae Infections ,Virology ,Cricetinae ,Chlorocebus aethiops ,Vaccine Development ,Vaccines and Antiviral Agents ,Influenza A virus ,medicine ,Animals ,Humans ,Mice, Inbred BALB C ,biology ,Influenza A Virus, H5N1 Subtype ,Viral Vaccine ,virus diseases ,RNA virus ,biology.organism_classification ,Macaca mulatta ,Influenza A virus subtype H5N1 ,Vaccination ,Influenza Vaccines ,Insect Science ,biology.protein ,Paramyxovirinae ,Female - Abstract
H5N1, an avian influenza virus, is known to circulate in many Asian countries, such as Bangladesh, China, Cambodia, Indonesia, and Vietnam. The current FDA-approved H5N1 vaccine has a moderate level of efficacy. A safe and effective vaccine is needed to prevent outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in humans. Nonsegmented negative-sense single-stranded viruses (NNSVs) are widely used as a vector to develop vaccines for humans, animals, and poultry. NNSVs stably express foreign genes without integrating with the host genome. J paramyxovirus (JPV) is a nonsegmented negative-strand RNA virus and a member of the proposed genus Jeilongvirus in the family Paramyxoviridae. JPV-specific antibodies have been detected in rodents, bats, humans, and pigs, but the virus is not associated with disease in any species other than mice. JPV replicates in the respiratory tract of mice and efficiently expresses the virus-vectored foreign genes in tissue culture cells. In this work, we explored JPV as a vector for developing an H5N1 vaccine using intranasal delivery. We incorporated hemagglutinin (HA) of H5N1 into the JPV genome by replacing the small hydrophobic (SH) gene to generate a recombinant JPV expressing HA (rJPV-ΔSH-H5). A single intranasal administration of rJPV-ΔSH-H5 protected mice from a lethal HPAI H5N1 challenge. Intranasal vaccination of rJPV-ΔSH-H5 in rhesus macaques elicited antigen-specific humoral and cell-mediated immune responses. This work demonstrates that JPV is a promising vaccine vector. IMPORTANCE A highly pathogenic avian influenza (HPAI) H5N1 outbreak in Southeast Asia destroyed millions of birds. Transmission of H5N1 into humans resulted in deaths in many countries. In this work, we developed a novel H5N1 vaccine candidate using J paramyxovirus (JPV) as a vector and demonstrated that JPV is an efficacious vaccine vector in animals. Nonsegmented negative-sense single-stranded viruses (NNSVs) stably express foreign genes without integrating into the host genome. JPV, an NNSV, replicates efficiently in the respiratory tract and induces robust immune responses.
- Published
- 2021
24. Age Associated Microbiome and Microbial Metabolites Modulation and Its Association With Systemic Inflammation in a Rhesus Macaque Model
- Author
-
Suresh Pallikkuth, Roberto Mendez, Kyle Russell, Tirupataiah Sirupangi, Daniel Kvistad, Rajendra Pahwa, Francois Villinger, Santanu Banerjee, and Savita Pahwa
- Subjects
Male ,Aging ,Immunology ,Inflammation ,microbiome and metabolites ,Systemic inflammation ,chemistry.chemical_compound ,Feces ,Immune system ,Immunity ,Tandem Mass Spectrometry ,medicine ,Immunology and Allergy ,Animals ,Microbiome ,immunity and microbiome ,Symbiosis ,Original Research ,age and immunity ,biology ,Bacteria ,Tumor Necrosis Factor-alpha ,Neopterin ,Immunosenescence ,RC581-607 ,biology.organism_classification ,Macaca mulatta ,Gastrointestinal Microbiome ,age and microbes ,Rhesus macaque ,Disease Models, Animal ,C-Reactive Protein ,age and metabolites ,chemistry ,Cytokines ,Dysbiosis ,Female ,medicine.symptom ,Immunologic diseases. Allergy - Abstract
Aging is associated with declining immunity and inflammation as well as alterations in the gut microbiome with a decrease of beneficial microbes and increase in pathogenic ones. The aim of this study was to investigate the age associated gut microbiome in relation to immunologic and metabolic profile in a non-human primate (NHP) model. 12 geriatric (age 19-24 years) and 4 young adult (age 3-4 years) Rhesus macaques were included in this study. Immune cell subsets were characterized in peripheral blood mononuclear cells (PBMC) by flow cytometry and plasma cytokines levels were determined by bead based multiplex cytokine analysis. Stool samples were collected by ileal loop and investigated for microbiome analysis by shotgun metagenomics. Serum, gut microbial lysate, and microbe-free fecal extract were subjected to metabolomic analysis by mass-spectrometry. Our results showed that the gut microbiome in geriatric animals had higher abundance of Archaeal and Proteobacterial species and lower Firmicutes than the young adults. Highly abundant microbes in the geriatric animals showed a direct association with plasma biomarkers of inflammation and immune activation such as neopterin, CRP, TNF, IL-2, IL-6, IL-8 and IFN-γ. Significant enrichment of metabolites that contribute to inflammatory and cytotoxic pathways was observed in serum and feces of geriatric animals compared to the young adults. We conclude that aging NHP undergo immunosenescence and age associated alterations in the gut microbiome that has a distinct metabolic profile. Aging NHP can serve as a model for investigating the relationship of the gut microbiome to particular age-associated comorbidities and for strategies aimed at modulating the microbiome.
- Published
- 2021
25. Viremia controls Env-specific antibody-secreting cell responses in simian immunodeficiency virus infected macaques pre and post-antiretroviral therapy
- Author
-
Jung Joo Hong, Eduardo Lani Volpe da Silveira, Praveen K. Amancha, Kenneth A. Rogers, Francois Villinger, Aftab A. Ansari, and Siddappa N. Byrareddy
- Subjects
viruses ,animal diseases ,Immunology ,Simian Acquired Immunodeficiency Syndrome ,Viremia ,HIV Infections ,Biology ,medicine.disease_cause ,Article ,medicine ,Immunology and Allergy ,Animals ,Memory B cell ,Lymph node ,B-Lymphocytes ,ELISPOT ,Monocyte ,virus diseases ,Simian immunodeficiency virus ,CARGA VIRAL ,Viral Load ,medicine.disease ,Macaca mulatta ,Infectious Diseases ,medicine.anatomical_structure ,Simian Immunodeficiency Virus ,Lymph ,Viral load - Abstract
OBJECTIVE The aim of this study was to investigate the kinetics of Env (gp140)-specific antibody-secreting cells (ASCs) during acute and early chronic simian immunodeficiency virus (SIV) infection, and prior to and postantiretroviral therapy (ART) in rhesus macaques. DESIGN AND METHODS At week 0, rhesus macaques were inoculated intravenously with SIVmac239 and the viral loads were allowed to develop. Daily ART was initiated at week 5 post infection until week 18, though the animals were monitored until week 28 for the following parameters: enumeration of SIV gp140-specific ASCs by ELISPOT; quantification of viremia and SIV gp140-specific IgG titres through qRT-PCR and ELISA, respectively; estimation of monocytes, follicular helper T cells (Tfh) and memory B cell frequencies using polychromatic flow cytometry. RESULTS Direct correlations were consistently found between blood SIV gp140-specific ASC responses and viremia or SIV Env-specific IgG titres. In contrast, SIV gp140-specific ASC responses showed inverse correlations with the percentage of total memory B cells in the blood. In lymph nodes, the magnitude of the SIV gp140-specific ASC responses also followed the viral load kinetics. In contrast, the number of SIV gp140-specific ASCs presented did not correlate with frequencies of circulating activated monocyte (CD14+CD16+) or Tfh cells. CONCLUSION Blood and/or lymph node viral loads may regulate the onset and magnitude of SIV gp140-specific ASCs during SIV infection and following ART in rhesus macaques.
- Published
- 2021
26. PET/CT targeted tissue sampling reveals virus specific dIgA can alter the distribution and localization of HIV after rectal exposure
- Author
-
Sidath C. Kumarapperuma, Thomas J. Hope, Kenneth A. Rogers, Peter T. Fox, Edward J. Allen, Ruth M. Ruprecht, Mariluz Araínga, Francois Villinger, Yanique Thomas, Ann M. Carias, Meegan R. Anderson, Sixia Xiao, Jeffrey R. Schneider, Siqi Gong, Michael D. McRaven, Angela J. Fought, Roslyn A. Taylor, Beth Goins, and Divya N. Thakkar
- Subjects
RNA viruses ,Physiology ,viruses ,Human immunodeficiency virus (HIV) ,HIV Infections ,HIV Antibodies ,Pathology and Laboratory Medicine ,medicine.disease_cause ,Biochemistry ,Virions ,Diagnostic Radiology ,0302 clinical medicine ,Immunodeficiency Viruses ,Immune Physiology ,Positron Emission Tomography Computed Tomography ,Medicine and Health Sciences ,Fluorescence microscope ,Mesenteric lymph nodes ,Biology (General) ,Tomography ,0303 health sciences ,Immune System Proteins ,biology ,Radiology and Imaging ,Immune complex ,medicine.anatomical_structure ,Medical Microbiology ,Viral Pathogens ,Viruses ,Anatomy ,Pathogens ,Antibody ,Research Article ,Colon ,Imaging Techniques ,QH301-705.5 ,Immunology ,Rectum ,Neuroimaging ,Viral Structure ,Research and Analysis Methods ,Microbiology ,Antibodies ,Virus ,Lymphatic System ,03 medical and health sciences ,Diagnostic Medicine ,In vivo ,Virology ,Retroviruses ,Fluorescence Imaging ,Genetics ,medicine ,Animals ,Distribution (pharmacology) ,Microbial Pathogens ,Molecular Biology ,030304 developmental biology ,PET-CT ,Mucous Membrane ,Lentivirus ,Organisms ,Biology and Life Sciences ,HIV ,Proteins ,RC581-607 ,Macaca mulatta ,Gastrointestinal Tract ,Immunoglobulin A, Secretory ,biology.protein ,Parasitology ,Lymph Nodes ,Immunologic diseases. Allergy ,Digestive System ,Positron Emission Tomography ,Neuroscience ,030215 immunology - Abstract
Human immunodeficiency virus (HIV) vaccines have not been successful in clinical trials. Dimeric IgA (dIgA) in the form of secretory IgA is the most abundant antibody class in mucosal tissues, making dIgA a prime candidate for potential HIV vaccines. We coupled Positron Emission Tomography (PET) imaging and fluorescent microscopy of 64Cu-labeled, photoactivatable-GFP HIV (PA-GFP-BaL) and fluorescently labeled dIgA to determine how dIgA antibodies influence virus interaction with mucosal barriers and viral penetration in colorectal tissue. Our results show that HIV virions rapidly disseminate throughout the colon two hours after exposure. The presence of dIgA resulted in an increase in virions and penetration depth in the transverse colon. Moreover, virions were found in the mesenteric lymph nodes two hours after viral exposure, and the presence of dIgA led to an increase in virions in mesenteric lymph nodes. Taken together, these technologies enable in vivo and in situ visualization of antibody-virus interactions and detailed investigations of early events in HIV infection., Author summary Vaccines provide protection in humans by eliciting the production of antibodies when exposed to a specific pathogen. Currently, an effective human immunodeficiency virus (HIV) vaccine does not exist. Since the beginning of the HIV epidemic, approximately 38 million people have died, creating the need to develop an HIV vaccine. The most common antibody in the organs that are exposed to HIV is dimeric IgA (dIgA). Here, we used multiple imaging techniques to determine how HIV travels throughout the colon once introduced into the body and how dIgA influences HIV movement in the rectum. We found that dIgA increased the amount of HIV found in the colon, the distance it travelled, and the depth into tissues that HIV penetrated. dIgA also increased the amount of HIV in the mesenteric lymph nodes two hours after viral exposure. Our study shows these imaging technologies can be used to examine interactions between viruses and antibodies in early HIV infection in the natural context of the anatomy and physiology of the rhesus macaque model.
- Published
- 2021
27. Cigarette smoke and HIV synergistically affect lung pathology in cynomolgus macaques
- Author
-
Shannon Callen, Vernat Exil, Madhavan Nair, Maria Cristina Vazquez Guillamet, Siddappa N. Byrareddy, Neerad C. Mishra, Francois Villinger, Jawad Abukhalaf, Rodrigo Vazquez-Guillamet, Shashi P. Singh, Karin Rudolph, Veena Raizada, Shilpa Buch, Shah S. Hussain, Aryaz Sheybani, Hitendra S. Chand, Hemant S. Agarwal, Christopher Royer, Mohan L. Sopori, and Edward G. Barrett
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Chronic bronchitis ,HIV Infections ,Cigarette Smoking ,Pulmonary Disease, Chronic Obstructive ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Metaplasia ,medicine ,Animals ,Lung ,Asthma ,COPD ,Goblet cell ,business.industry ,Concise Communication ,virus diseases ,General Medicine ,respiratory system ,Hyperplasia ,medicine.disease ,respiratory tract diseases ,Pulmonary Alveoli ,Macaca fascicularis ,030104 developmental biology ,medicine.anatomical_structure ,Pulmonology ,030228 respiratory system ,Immunology ,HIV-1 ,medicine.symptom ,business - Abstract
In the era of combined antiretroviral therapy (cART), lung diseases such as chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) are common among persons living with HIV (PLWH), particularly smokers. Although smoking is highly prevalent among PLWH, HIV may be an independent risk factor for lung diseases; however, the role of HIV and cigarette smoke (CS) and their potential interaction in the development of chronic lung diseases among PLWH has not been delineated. To investigate this interaction, cynomolgus macaques were exposed to CS and/or simian-adapted human immunodeficiency virus (SHIV) and treated with cART. The development of CB and the lung functions were evaluated following CS±SHIV treatment. The results showed that in the lung, SHIV was a strong independent risk factor for goblet cell metaplasia/hyperplasia and mucus formation, MUC5AC synthesis, loss of tight junction proteins, and increased expression of Th2 cytokines/transcription factors. In addition, SHIV and CS synergistically reduced lung function and increased extrathoracic tracheal ring thickness. Interestingly, SHIV infection generated significant numbers of HIV-gp120(+) epithelial cells (HGECs) in small airways and alveoli, and their numbers doubled in CS+SHIV-infected lungs. We conclude that even with cART, SHIV independently induces CB and pro-COPD changes in the lung, and the effects are exacerbated by CS.
- Published
- 2018
28. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
- Author
-
Bali Pulendran, Allison J. Greaney, Max Johnson, Brooke Fiala, Ralph S. Baric, Jesse D. Bloom, Tyler N. Starr, Elizabeth Kepl, Rashmi Ravichandran, David Veesler, Roland Tisch, Mary-Jane Navarro, Kenneth A. Rogers, Kaitlin R. Sprouse, Kelly D. Smith, Natalie Brunette, Megan A. O'Connor, M. Alejandra Tortorici, Douglas E. Ferrell, Davide Corti, Prabhu S. Arunachalam, Timothy P. Sheahan, Samuel Wrenn, Robbert van der Most, Sarah R. Leist, Lisa Shirreff, Harry Kleanthous, Marcos C. Miranda, Alyssa Blackstone, Claire Sydeman, Francois Villinger, Jason S. McLellan, Deleah Pettie, David R. Martinez, Cassandra Ogohara, Minh N. Pham, Lauren Carter, Wesley C. Van Voorhis, Deborah H. Fuller, Samantha K Zepeda, Alexandra Schäfer, Sasha W Tilles, Matthew Clark, Alexandra C. Walls, Rino Rappuoli, John E. Bowen, Neil P. King, Derek T. O'Hagan, and Ching-Lin Hsieh
- Subjects
2019-20 coronavirus outbreak ,Immunogen ,Coronavirus disease 2019 (COVID-19) ,biology ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,fungi ,Mutant ,Antibody titer ,COVID-19 ,Virology ,General Biochemistry, Genetics and Molecular Biology ,Article ,Neutralization ,Immunization ,Antigen ,Polyclonal antibodies ,Immunity ,vaccine design ,biology.protein ,receptor-binding domain ,Antibody ,spike glycoprotein - Abstract
Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is key for guiding public health policies. We show that a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine (RBD-NP) protects mice from SARS-CoV-2 challenge after a single immunization, indicating a potential dose-sparing strategy. We benchmarked serum neutralizing activity elicited by RBD-NP in non-human primates against a lead prefusion-stabilized SARS-CoV-2 spike (HexaPro) using a panel of circulating mutants. Polyclonal antibodies elicited by both vaccines are similarly resilient to many RBD residue substitutions tested although mutations at and surrounding position 484 have negative consequences for neutralization. Mosaic and cocktail nanoparticle immunogens displaying multiple sarbecovirus RBDs elicit broad neutralizing activity in mice and protect mice against SARS-CoV challenge even in the absence of SARS-CoV RBD in the vaccine. This study provides proof of principle that multivalent sarbecovirus RBD-NPs induce heterotypic protection and motivates advancing such broadly protective sarbecovirus vaccines to the clinic., A clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine (RBD-NP) is protective in mice after a single immunization and elicits strong antibody responses across circulating mutants and broader sarbecoviruses. Multivalent sarbecovirus RBD-NPs can heterotypic protection as serve as a broad therapeutic against coronaviruses.
- Published
- 2021
29. Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages
- Author
-
Lynn Morris, Francois Villinger, Rosamund Chapman, Gerald K. Chege, Alana Keyser, Craig H. Adams, Anna-Lise Williamson, and Valerie Bekker
- Subjects
0301 basic medicine ,Serial dilution ,T cell ,Simian Acquired Immunodeficiency Syndrome ,lcsh:QR1-502 ,Virus Replication ,Virus ,Article ,lcsh:Microbiology ,Cell Line ,03 medical and health sciences ,0302 clinical medicine ,Chinese rhesus macaques ,In vivo ,Virology ,medicine ,Animals ,Humans ,030212 general & internal medicine ,Serial Passage ,Immunodeficiency ,biology ,SAIDS Vaccines ,Viral Load ,Vaccine efficacy ,medicine.disease ,Macaca mulatta ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,Viral replication ,SHIV ,biology.protein ,Simian Immunodeficiency Virus ,subtype C ,Antibody - Abstract
Rhesus macaques can be readily infected with chimeric simian-human immunodeficiency viruses (SHIV) as a suitable virus challenge system for testing the efficacy of HIV vaccines. Three Chinese-origin rhesus macaques (ChRM) were inoculated intravenously (IV) with SHIVC109P4 in a rapid serial in vivo passage. SHIV recovered from the peripheral blood of the final ChRM was used to generate a ChRM-adapted virus challenge stock. This stock was titrated for the intrarectal route (IR) in 8 ChRMs using undiluted, 1:10 or 1:100 dilutions, to determine a suitable dose for use in future vaccine efficacy testing via repeated low-dose IR challenges. All 11 ChRMs were successfully infected, reaching similar median peak viraemias at 1–2 weeks post inoculation but undetectable levels by 8 weeks post inoculation. T-cell responses were detected in all animals and Tier 1 neutralizing antibodies (Nab) developed in 10 of 11 infected ChRMs. All ChRMs remained healthy and maintained normal CD4+ T cell counts. Sequence analyses showed >, 98% amino acid identity between the original inoculum and virus recovered at peak viraemia indicating only minimal changes in the env gene. Thus, while replication is limited over time, our adapted SHIV can be used to test for protection of virus acquisition in ChRMs.
- Published
- 2021
- Full Text
- View/download PDF
30. Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates
- Author
-
Pooja M. Tiwari, Krista Dienger-Stambaugh, Peng Xiao, Ashley C. Beavis, Huiling Wei, Biao He, Shannon Phan, Nihar R. Deb Adhikary, Xuemin Chen, Paul Spearman, Francois Villinger, and Karnail Singh
- Subjects
Male ,0301 basic medicine ,T-Lymphocytes ,viruses ,human immunodeficiency virus (HIV) vaccine ,Antibodies, Viral ,Neutralization ,Immunogenicity, Vaccine ,0302 clinical medicine ,Virus-like particle ,Vaccines, DNA ,Immunology and Allergy ,030212 general & internal medicine ,HIV vaccine ,Original Research ,AIDS Vaccines ,Antibody-dependent cell-mediated cytotoxicity ,Immunity, Cellular ,Vaccination ,env Gene Products, Human Immunodeficiency Virus ,Antibody titer ,virus diseases ,medicine.anatomical_structure ,virus-like particles (VLP) ,Host-Pathogen Interactions ,Simian Immunodeficiency Virus ,lcsh:Immunologic diseases. Allergy ,T cell ,Immunology ,Gene Products, gag ,parainfluenza virus 5 (PIV5) ,Biology ,complex mixtures ,Cell Line ,rhesus macaques ,03 medical and health sciences ,Immune system ,Immunity ,medicine ,Animals ,Immunity, Mucosal ,Administration, Intranasal ,Virion ,Macaca mulatta ,Virology ,immune responses ,Immunity, Humoral ,Nasal Mucosa ,030104 developmental biology ,HIV-1 ,Parainfluenza Virus 5 ,Cattle ,lcsh:RC581-607 - Abstract
The search for a preventive vaccine against HIV infection remains an ongoing challenge, indicating the need for novel approaches. Parainfluenza virus 5 (PIV5) is a paramyxovirus replicating in the upper airways that is not associated with any animal or human pathology. In animal models, PIV5-vectored vaccines have shown protection against influenza, RSV, and other human pathogens. Here, we generated PIV5 vaccines expressing HIV envelope (Env) and SIV Gag and administered them intranasally to macaques, followed by boosting with virus-like particles (VLPs) containing trimeric HIV Env. Moreover, we compared the immune responses generated by PIV5-SHIV prime/VLPs boost regimen in naïve vs a control group in which pre-existing immunity to the PIV5 vector was established. We demonstrate for the first time that intranasal administration of PIV5-based HIV vaccines is safe, well-tolerated and immunogenic, and that boosting with adjuvanted trimeric Env VLPs enhances humoral and cellular immune responses. The PIV5 prime/VLPs boost regimen induced robust and durable systemic and mucosal Env-specific antibody titers with functional activities including ADCC and neutralization. This regimen also induced highly polyfunctional antigen-specific T cell responses. Importantly, we show that diminished responses due to PIV5 pre-existing immunity can be overcome in part with VLP protein boosts. Overall, these results establish that PIV5-based HIV vaccine candidates are promising and warrant further investigation including moving on to primate challenge studies.
- Published
- 2021
31. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
- Author
-
Bali Pulendran, David Novack, Deleah Pettie, Jay Rappaport, Xiaoying Shen, Ching-Lin Hsieh, Rudolph B Bohm, Alexandra C. Walls, Elizabeth Kepl, David Veesler, Shankar Subramaniam, Rino Rappuoli, Harry Kleanthous, Claire Sydeman, Derek T O Hagan, Alex Lee Zhu, JoAnne L. Flynn, Robbert van der Most, Christopher Monjure, Kenneth S. Plante, Francois Villinger, Prabhu S. Arunachalam, Nicholas J. Maness, Pyone P. Aye, Sally Shin, Matthew J. Gorman, Natalie Brunette, Michael E. P. Murphy, Lilin Lai, Scott D. Boyd, Caroline Atyeo, Katharina Röltgen, Venkata Viswanadh Edara, Robert L Coffman, Chad J. Roy, Kasi E. Russell-Lodrigue, David C. Montefiori, Nadia A. Golden, Meera Trisal, Jessica A. Plante, John C. Kraft, Mehul S. Suthar, Jason Dufour, Kenneth A. Rogers, Marcos C. Miranda, Lisa Shirreff, Brooke Fiala, Samuel Wrenn, Lara Doyle-Meyer, Shakti Gupta, Douglas E. Ferrell, Jane Fontenot, Jason S. McLellan, Lauren Carter, Mary Jane Navarro, Alexander G. White, Stephanie Fischinger, Neil P. King, Galit Alter, and Chunfeng Li
- Subjects
Agonist ,Immunogen ,biology ,business.industry ,medicine.drug_class ,Alum ,medicine.medical_treatment ,Virology ,chemistry.chemical_compound ,Immunization ,chemistry ,Immunity ,medicine ,biology.protein ,AS03 ,business ,Neutralizing antibody ,Adjuvant - Abstract
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike protein receptor binding domain displayed on a two-component protein nanoparticle (RBD-NP), to stimulate robust and durable neutralizing antibody (nAb) responses and protection against SARS-CoV-2 in non-human primates. We evaluated five different adjuvants combined with RBD-NP including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an alpha-tocopherol-containing squalene-based oil-in-water emulsion used in pandemic influenza vaccines; AS37, a TLR-7 agonist adsorbed to Alum; CpG 1018-Alum (CpG-Alum), a TLR-9 agonist formulated in Alum; or Alum, the most widely used adjuvant. All five adjuvants induced substantial nAb and CD4 T cell responses after two consecutive immunizations. Durable nAb responses were evaluated for RBD-NP/AS03 immunization and the live-virus nAb response was durably maintained up to 154 days post-vaccination. AS03, CpG-Alum, AS37 and Alum groups conferred significant protection against SARS-CoV-2 infection in the pharynges, nares and in the bronchoalveolar lavage. The nAb titers were highly correlated with protection against infection. Furthermore, RBD-NP when used in conjunction with AS03 was as potent as the prefusion stabilized Spike immunogen, HexaPro. Taken together, these data highlight the efficacy of the RBD-NP formulated with clinically relevant adjuvants in promoting robust immunity against SARS-CoV-2 in non-human primates.
- Published
- 2021
32. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- Author
-
Prabhu S, Arunachalam, Alexandra C, Walls, Nadia, Golden, Caroline, Atyeo, Stephanie, Fischinger, Chunfeng, Li, Pyone, Aye, Mary Jane, Navarro, Lilin, Lai, Venkata Viswanadh, Edara, Katharina, Röltgen, Kenneth, Rogers, Lisa, Shirreff, Douglas E, Ferrell, Samuel, Wrenn, Deleah, Pettie, John C, Kraft, Marcos C, Miranda, Elizabeth, Kepl, Claire, Sydeman, Natalie, Brunette, Michael, Murphy, Brooke, Fiala, Lauren, Carter, Alexander G, White, Meera, Trisal, Ching-Lin, Hsieh, Kasi, Russell-Lodrigue, Christopher, Monjure, Jason, Dufour, Skye, Spencer, Lara, Doyle-Meyers, Rudolph P, Bohm, Nicholas J, Maness, Chad, Roy, Jessica A, Plante, Kenneth S, Plante, Alex, Zhu, Matthew J, Gorman, Sally, Shin, Xiaoying, Shen, Jane, Fontenot, Shakti, Gupta, Derek T, O'Hagan, Robbert, Van Der Most, Rino, Rappuoli, Robert L, Coffman, David, Novack, Jason S, McLellan, Shankar, Subramaniam, David, Montefiori, Scott D, Boyd, JoAnne L, Flynn, Galit, Alter, Francois, Villinger, Harry, Kleanthous, Jay, Rappaport, Mehul S, Suthar, Neil P, King, David, Veesler, and Bali, Pulendran
- Subjects
CD4-Positive T-Lymphocytes ,Male ,Squalene ,Immunity, Cellular ,COVID-19 Vaccines ,Clinical Trials, Phase I as Topic ,SARS-CoV-2 ,COVID-19 ,Antibodies, Viral ,Antibodies, Neutralizing ,Macaca mulatta ,Article ,Immunity, Humoral ,Disease Models, Animal ,Clinical Trials, Phase II as Topic ,Adjuvants, Immunologic ,Oligodeoxyribonucleotides ,Spike Glycoprotein, Coronavirus ,Vaccines, Subunit ,Alum Compounds ,Animals - Abstract
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike protein receptor-binding domain displayed on a two-component protein nanoparticle (RBD-NP), to stimulate robust and durable neutralizing antibody (nAb) responses and protection against SARS-CoV-2 in non-human primates. We evaluated five different adjuvants combined with RBD-NP including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an alpha-tocopherol-containing squalene-based oil-in-water emulsion used in pandemic influenza vaccines; AS37, a TLR-7 agonist adsorbed to Alum; CpG 1018-Alum (CpG-Alum), a TLR-9 agonist formulated in Alum; or Alum, the most widely used adjuvant. All five adjuvants induced substantial nAb and CD4 T cell responses after two consecutive immunizations. Durable nAb responses were evaluated for RBD-NP/AS03 immunization and the live-virus nAb response was durably maintained up to 154 days post-vaccination. AS03, CpG-Alum, AS37 and Alum groups conferred significant protection against SARS-CoV-2 infection in the pharynges, nares and in the bronchoalveolar lavage. The nAb titers were highly correlated with protection against infection. Furthermore, RBD-NP when used in conjunction with AS03 was as potent as the prefusion stabilized Spike immunogen, HexaPro. Taken together, these data highlight the efficacy of the RBD-NP formulated with clinically relevant adjuvants in promoting robust immunity against SARS-CoV-2 in non-human primates.
- Published
- 2021
33. Simian Immunodeficiency Virus Susceptibility, Immunology, and Microbiome in the Female Genital Tract of Adolescent Versus Adult Pigtail Macaques
- Author
-
Alicia R, Berard, Charlene, Miller, Mariluz, Araínga, Courtney Ann, Broedlow, Laura, Noël-Romas, Luca, Schifanella, Tiffany, Hensley-McBain, Alex, Roederer, Connor B, Driscoll, Ernesto, Coronado, Jennifer, Manuzak, Lyle R, McKinnon, Francois, Villinger, Thomas J, Hope, Adam D, Burgener, and Nichole R, Klatt
- Subjects
Adult ,Proteomics ,Adolescent ,Microbiota ,Simian Acquired Immunodeficiency Syndrome ,HIV Infections ,Genitalia, Female ,RNA, Ribosomal, 16S ,Animal Studies ,Animals ,Humans ,Female ,Simian Immunodeficiency Virus ,Macaca nemestrina - Abstract
In Sub-Saharan Africa, young women 15–24 years of age account for nearly 30% of all new HIV infections, however, biological and epidemiological factors underlying this disproportionate infection rate are unclear. In this study, we assessed biological contributors of SIV/HIV susceptibility in the female genital tract (FGT) using adolescent (n = 9) and adult (n = 10) pigtail macaques (PTMs) with weekly low-dose intravaginal challenges of SIV. Immunological variables were captured in vaginal tissue of PTMs by flow cytometry and cytokine assays. Vaginal biopsies were profiled by proteomic analysis. The vaginal microbiome was assessed by 16S rRNA sequencing. We were powered to detect a 2.2-fold increase in infection rates between age groups, however, we identified no significant differences in susceptibility. This model cannot capture epidemiological factors or may not best represent biological differences of HIV susceptibility. No immune cell subsets measured were significantly different between groups. Inflammatory marker MCP-1 was significantly higher (adj p = .02), and sCD40L trended higher (adj p = .06) in vaginal cytobrushes of adults. Proteomic analysis of vaginal biopsies showed no significant (adj p
- Published
- 2021
34. SIV susceptibility, immunology and microbiome in the female genital tract of adolescent versus adult pigtail macaques
- Author
-
Laura Noël-Romas, Francois Villinger, Connor B. Driscoll, Tiffany Hensley-McBain, Alex Roederer, Jennifer A. Manuzak, Adam Burgener, Luca Schifanella, Courtney Broedlow, Alicia R. Berard, Nichole R. Klatt, Ernesto Coronado, Mariluz Araínga, Lyle R. McKinnon, Thomas J. Hope, and Charlene Miller
- Subjects
0301 basic medicine ,Female circumcision ,Non human primate ,biology ,Epidemiological Factors ,business.industry ,Immunology ,Human immunodeficiency virus (HIV) ,Pigtail macaque ,Simian immunodeficiency virus ,biology.organism_classification ,medicine.disease_cause ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Infectious Diseases ,Virology ,parasitic diseases ,Vaginal microbiome ,medicine ,030212 general & internal medicine ,Microbiome ,business - Abstract
In Sub-Saharan Africa, young women 15–24 years of age account for nearly 30% of all new HIV infections, however, biological and epidemiological factors underlying this disproportionate infection ra...
- Published
- 2021
35. CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis
- Author
-
Daria M. Potashnikova, Souheil-Antoine Younes, Francois Villinger, Karem C. Harth, Scott F. Sieg, Vikram S. Kashyap, Gillian M. Michaelson, Elena Vasilieva, Jonathan M Wyrick, Stephen R. Morris, Michael L. Freeman, Bonnie Chen, Nicholas T. Funderburg, Michael M. Lederman, Alexey A. Komissarov, Soumya Panigrahi, Mark J. Cameron, Mirko Paiardini, Mike Fang, Cheryl M. Cameron, A. Lebedeva, Leonid Margolis, and David A. Zidar
- Subjects
HIV Infections ,Cardiovascular Medicine ,CD8-Positive T-Lymphocytes ,Vascular Medicine ,Epithelium ,White Blood Cells ,Medical Conditions ,Animal Cells ,Medicine and Health Sciences ,Cytotoxic T cell ,Biology (General) ,Aorta ,Interleukin-15 ,0303 health sciences ,education.field_of_study ,T Cells ,030302 biochemistry & molecular biology ,medicine.anatomical_structure ,Cardiovascular Diseases ,Interleukin 15 ,Infectious diseases ,Receptors, Chemokine ,Tumor necrosis factor alpha ,Cellular Types ,Anatomy ,Research Article ,Endothelium ,QH301-705.5 ,Immune Cells ,T cell ,Immunology ,Population ,Cardiology ,Cytotoxic T cells ,Viral diseases ,Microbiology ,Endothelial activation ,03 medical and health sciences ,Virology ,Genetics ,medicine ,Animals ,Humans ,CX3CL1 ,education ,Molecular Biology ,Aged ,030304 developmental biology ,Blood Cells ,Chemokine CX3CL1 ,business.industry ,Biology and Life Sciences ,Endothelial Cells ,Epithelial Cells ,Cell Biology ,RC581-607 ,Atherosclerosis ,Macaca mulatta ,Biological Tissue ,Cardiovascular Anatomy ,Blood Vessels ,Parasitology ,Immunologic diseases. Allergy ,business - Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains an important cause of morbidity in the general population and risk for ASCVD is increased approximately 2-fold in persons living with HIV infection (PLWH). This risk is linked to elevated CD8 T cell counts that are abundant in atherosclerotic plaques and have been implicated in disease pathogenesis yet the mechanisms driving T cell recruitment to and activation within plaques are poorly defined. Here we investigated the role of CD8 T cells in atherosclerosis in a non-human primate model of HIV infection and in the HIV-uninfected elderly; we sought to identify factors that promote the activation, function, and recruitment to endothelium of CX3CR1+ CD8 T cells. We measured elevated expression of CX3CL1 and IL-15, and increased CD8 T cell numbers in the aortas of rhesus macaques infected with SIV or SHIV, and demonstrated similar findings in atherosclerotic vessels of HIV-uninfected humans. We found that recombinant TNF enhanced the production and release of CX3CL1 and bioactive IL-15 from aortic endothelial cells, but not from aortic smooth muscle cells. IL-15 in turn promoted CX3CR1 surface expression on and TNF synthesis by CD8 T cells, and IL-15-treated CD8 T cells exhibited enhanced CX3CL1-dependent chemoattraction toward endothelial cells in vitro. Finally, we show that CD8 T cells in human atherosclerotic plaques have an activated, resident phenotype consistent with in vivo IL-15 and CX3CL1 exposure. In this report, we define a novel model of CD8 T cell involvement in atherosclerosis whereby CX3CL1 and IL-15 operate in tandem within the vascular endothelium to promote infiltration by activated CX3CR1+ memory CD8 T cells that drive further endothelial activation via TNF. We propose that these interactions are prevalent in aging and in PLWH, populations where circulating activated CX3CR1+ CD8 T cell numbers are often expanded., Author summary People living with HIV infection and elderly HIV-uninfected persons have increased risk of developing atherosclerotic cardiovascular disease, and have increased numbers and/or proportions of CD8 T cells that express the vascular endothelium-homing receptor CX3CR1. Atherosclerotic plaques contain many activated CD8 T cells, which have been implicated in disease pathogenesis, yet the mechanisms driving T cell recruitment to and activation within plaques are not clear. Here we propose a model in which CX3CR1+ CD8 T cells promote endothelial dysfunction by the combined effects of CX3CL1, IL-15, and TNF. Persistent inflammation triggers endothelial cell activation and dysfunction in people living with HIV infection. Endothelial cell-derived CX3CL1 then directs the migration of CX3CR1+ T cells to the activated endothelium where IL-15 activates T cells to express TNF. TNF drives endothelial expression of CX3CL1 and IL-15, providing a feed-forward loop of activation. We provide evidence that these pathways are active in human atherosclerotic plaques and in the aortic endothelium of SIV/SHIV-infected rhesus macaques. We propose these mechanisms of T cell-induced endothelial damage are operative in traditional risk factor-associated atherosclerosis in the general population and are accelerated in people with HIV infection who live in a state of sustained chronic inflammation.
- Published
- 2020
36. IL-21 and IFNα therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques
- Author
-
Steven E. Bosinger, Jeffrey D. Lifson, Kirk Easley, Francois Villinger, Hong Wang, Philippe Rascle, Luca Micci, Guido Silvestri, Neeta Shenvi, Gregory K. Tharp, Nicolas Huot, Cristin M. Galardi, Colin T. King, Michaela Müller-Trutwin, Justin L. Harper, Amit A. Upadhyay, Beatrice Jacquelin, Mirko Paiardini, Emory University [Atlanta, GA], HIV, Inflammation et persistance, Institut Pasteur [Paris], Université Paris Diderot, Sorbonne Paris Cité, Paris, France, Université Paris Diderot - Paris 7 (UPD7), University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), ViiV Healthcare US, ViiV Healthcare [Brentford, UK], University of Louisiana, Frederick National Laboratory for Cancer Research (FNLCR), Emory University School of Medicine, This work was supported by the NIAID, NIH under award number R01AI116379 to M. P. and R01AI143457 to M. M.-T. Support for this work was also provided by ANRS and the Fondation J. Beytout to M. M.-T., NCRR, NIH award 5R24RR016988 to F. V. and the Resource for Nonhuman Primate Immune Reagents, ORIP/OD award P51OD011132 to YNPRC, and NCI, NIH award HHSN261200800001E and 75N91019D00024 to Leidos Biomedical Research. P.R. was recipient of a PhD fellowship from the University Paris Diderot, Sorbonne Paris Cité., HIV, Inflammation et persistance - HIV, Inflammation and Persistence, and Institut Pasteur [Paris] (IP)
- Subjects
0301 basic medicine ,CD4-Positive T-Lymphocytes ,animal diseases ,Science ,[SDV]Life Sciences [q-bio] ,Immunology ,Simian Acquired Immunodeficiency Syndrome ,General Physics and Astronomy ,Alpha interferon ,Inflammation ,Lymphocyte Activation ,Antiviral Agents ,General Biochemistry, Genetics and Molecular Biology ,Article ,Natural killer cell ,Natural killer cell differentiation ,03 medical and health sciences ,Interferon-gamma ,0302 clinical medicine ,Interferon ,medicine ,Animals ,Viremia ,Lymph node ,Multidisciplinary ,biology ,Interleukins ,virus diseases ,General Chemistry ,Viral host response ,Viral Load ,biology.organism_classification ,Virology ,Macaca mulatta ,3. Good health ,Killer Cells, Natural ,Rhesus macaque ,030104 developmental biology ,medicine.anatomical_structure ,Anti-Retroviral Agents ,030220 oncology & carcinogenesis ,Female ,Simian Immunodeficiency Virus ,African Green Monkey ,Immunotherapy ,medicine.symptom ,medicine.drug ,HIV infections - Abstract
Unlike HIV infection, which progresses to AIDS absent suppressive anti-retroviral therapy, nonpathogenic infections in natural hosts, such African green monkeys, are characterized by a lack of gut microbial translocation and robust secondary lymphoid natural killer cell responses resulting in an absence of chronic inflammation and limited SIV dissemination in lymph node B-cell follicles. Here we report, using the pathogenic model of antiretroviral therapy-treated, SIV-infected rhesus macaques that sequential interleukin-21 and interferon alpha therapy generate terminally differentiated blood natural killer cells (NKG2a/clowCD16+) with potent human leukocyte antigen-E-restricted activity in response to SIV envelope peptides. This is in contrast to control macaques, where less differentiated, interferon gamma-producing natural killer cells predominate. The frequency and activity of terminally differentiated NKG2a/clowCD16+ natural killer cells correlates with a reduction of replication-competent SIV in lymph node during antiretroviral therapy and time to viral rebound following analytical treatment interruption. These data demonstrate that African green monkey-like natural killer cell differentiation profiles can be rescued in rhesus macaques to promote viral clearance in tissues., Infection of African green monkeys with SIV is associated with reduced pathogenicity. Here the authors explore the requirement of differentiated NK cell populations in a pathogenic Rhesus macaque model of SIV infection and show administration of IL-21 and IFNα rescues terminally differentiated NK cells, similarly to what found in African green monkeys, and limits the SIV reservoir in antiretroviral therapy treated macaques.
- Published
- 2020
37. Safety and Immunological Evaluation of Interleukin-21 Plus Anti-α4β7 mAb Combination Therapy in Rhesus Macaques
- Author
-
Maria Pino, Srijayaprakash Babu Uppada, Kabita Pandey, Colin King, Kevin Nguyen, Inbo Shim, Kenneth Rogers, Francois Villinger, Mirko Paiardini, and Siddappa N. Byrareddy
- Subjects
lcsh:Immunologic diseases. Allergy ,0301 basic medicine ,Integrins ,anti-α4β7 ,Combination therapy ,macaques ,medicine.drug_class ,Immunology ,Biological Availability ,Viremia ,Inflammation ,medicine.disease_cause ,Monoclonal antibody ,immune activation ,rhesus macaques ,03 medical and health sciences ,Interleukin 21 ,0302 clinical medicine ,Isoantibodies ,IL-21 ,Animals ,Humans ,Immunology and Allergy ,Medicine ,Original Research ,biology ,business.industry ,Interleukins ,Immunity ,Antibodies, Monoclonal ,Simian immunodeficiency virus ,medicine.disease ,Macaca mulatta ,Immunoglobulin Fc Fragments ,Killer Cells, Natural ,T- cell homing ,combined immune intervention ,030104 developmental biology ,Leukocytes, Mononuclear ,biology.protein ,Drug Therapy, Combination ,medicine.symptom ,Antibody ,lcsh:RC581-607 ,business ,Biomarkers ,030215 immunology ,Homing (hematopoietic) - Abstract
Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections compromise gut immunological barriers, inducing high levels of inflammation and a severe depletion of intestinal CD4+ T cells. Expression of α4β7 integrin promotes homing of activated T cells to intestinal sites where they become preferentially infected; blockade of α4β7 with an anti-α4β7 monoclonal antibody (mAb) prior to infection has been reported to reduce gut SIV viremia in rhesus macaques (RMs). Interleukin-21 (IL-21) administration in antiretroviral therapy-treated, SIV-infected RMs reduces gut inflammation and improves gut integrity. We therefore hypothesized that the combination of IL-21 and anti-α4β7 mAb therapies could synergize to reduce inflammation and HIV persistence. We co-administered two intravenous doses of rhesus anti-α4β7 mAb (50 mg/kg) combined with seven weekly subcutaneous infusions of IL-21–IgFc (100 μg/kg) in four healthy, SIV-uninfected RMs to evaluate the safety and immunological profiles of this intervention in blood and gut. Co-administration of IL-21 and anti-α4β7 mAb showed no toxicity at the given dosages as assessed by multiple hematological and chemical parameters and did not alter the bioavailability of the therapeutics or result in the generation of antibodies against the anti-α4β7 mAb or IL-21–IgFc. Upon treatment, the frequency of CD4 memory T cells expressing β7 increased in blood and decreased in gut, consistent with an inhibition of activated CD4 T-cell homing to the gut. Furthermore, the frequency of T cells expressing proliferation and immune activation markers decreased in blood and, more profoundly, in gut. The combined IL-21 plus anti-α4β7 mAb therapy is well-tolerated in SIV-uninfected RMs and reduces the gut homing of α4β7+ CD4 T cells as well as the levels of gut immune activation.
- Published
- 2020
38. Morphine Potentiates Dysbiotic Microbial and Metabolic Shifts in Acute SIV Infection
- Author
-
Gregory M. Sindberg, Vanessa L. Hale, Shilpa Buch, Shannon Callen, Jingjing Meng, Francois Villinger, Paul D. Cheney, Sabita Roy, Santanu Banerjee, and Ramakrishna Hegde
- Subjects
CD4-Positive T-Lymphocytes ,Male ,0301 basic medicine ,Immunology ,Simian Acquired Immunodeficiency Syndrome ,Neuroscience (miscellaneous) ,Context (language use) ,Chromosomal translocation ,Inflammation ,medicine.disease_cause ,Article ,Pathogenesis ,Feces ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,RNA, Ribosomal, 16S ,medicine ,Animals ,Immunology and Allergy ,Pharmacology ,Morphine ,business.industry ,virus diseases ,Viral Load ,Simian immunodeficiency virus ,medicine.disease ,Macaca mulatta ,Gastrointestinal Microbiome ,Analgesics, Opioid ,030104 developmental biology ,Opioid ,Simian Immunodeficiency Virus ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
BACKGROUND: Human Immunodeficiency Virus (HIV) pathogenesis has been closely linked with microbial translocation, which is believed to drive inflammation and HIV replication. Opioid drugs have been shown to worsen this symptom, leading to a faster progression of HIV infection to Acquired Immunodeficiency Syndrome (AIDS). The interaction of HIV and opioid drugs has not been studied at early stages of HIV, particularly in the gut microbiome where changes may precede translocation events. METHODS: This study modeled early HIV infection by examining Simian Immunodeficiency Virus (SIV)-infected primates at 21 days or less both independently and in the context of opioid use. Fecal samples were analyzed both for 16S analysis of microbial populations as well as metabolite profiles via mass spectrometry. RESULTS: Our results indicate that changes are minor in SIV treated animals in the time points examined, however animals treated with morphine and SIV had significant changes in their microbial communities and metabolic profiles. This occurred in a time-independent fashion with morphine regardless of how long the animal had morphine in its system. CONCLUSIONS: Globally, the observed changes support that microbial dysbiosis is occurring in these animals at an early time, which likely contributes to the translocation events observed later in SIV/HIV pathogenesis. Additionally, metabolic changes were predictive of specific treatment groups, which could be further developed as a diagnostic tool or future intervention target to overcome and slow the progression of HIV infection to AIDS.
- Published
- 2018
39. MAdCAM costimulation through Integrin-α4β7 promotes HIV replication
- Author
-
Elena Martinelli, Claudia Cicala, Jocelyn C Ray, Marcelo A. Soares, James Arthos, Donald Van Ryk, Mark Connors, Mia Waliszewski, Joseph Hiatt, Danlan Wei, Francois Villinger, Aftab A. Ansari, Ian Perrone, Fatima Nawaz, Stephen A. Migueles, Alia Sajani, Ronke Olowojesiku, Anthony S. Fauci, Katija Jelicic, and Livia R. Goes
- Subjects
0301 basic medicine ,Immunology ,High endothelial venules ,Integrin ,Retinoic acid ,Biology ,3. Good health ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,chemistry ,Viral replication ,Downregulation and upregulation ,Monoclonal ,Addressin ,biology.protein ,Cancer research ,Immunology and Allergy ,Antibody - Abstract
Human gut-associated lymphoid tissues (GALT) play a key role in the acute phase of HIV infection. The propensity of HIV to replicate in these tissues, however, is not fully understood. Access and migration of naive and memory CD4+ T cells to these sites is mediated by interactions between integrin α4β7, expressed on CD4+ T cells, and MAdCAM, expressed on high endothelial venules. We report here that MAdCAM delivers a potent costimulatory signal to naive and memory CD4+ T cells following ligation with α4β7. Such costimulation promotes high levels of HIV replication. An anti-α4β7 mAb that prevents mucosal transmission of SIV blocks MAdCAM signaling through α4β7 and MAdCAM-dependent viral replication. MAdCAM costimulation of memory CD4+ T cells is sufficient to drive cellular proliferation and the upregulation of CCR5, while naive CD4+ T cells require both MAdCAM and retinoic acid to achieve the same response. The pairing of MAdCAM and retinoic acid is unique to the GALT, leading us to propose that HIV replication in these sites is facilitated by MAdCAM-α4β7 interactions. Moreover, complete inhibition of MAdCAM signaling by an anti-α4β7 mAb, an analog of the clinically approved therapeutic vedolizumab, highlights the potential of such agents to control acute HIV infection.
- Published
- 2018
40. Compromised steady‐state germinal center activity with age in nonhuman primates
- Author
-
Francois Villinger, Tirupataiah Sirupangi, Rajendra Pahwa, Lucio Gama, Kimberly Shankwitz, Kyle Blaine Russel, Constantinos Petrovas, Suresh Pallikkuth, Savita Pahwa, Richard A. Koup, Daniel Kvistad, and Li Pan
- Subjects
CD4-Positive T-Lymphocytes ,0301 basic medicine ,Aging ,medicine.medical_specialty ,Cell ,CD8-Positive T-Lymphocytes ,Biology ,Positive correlation ,Monocytes ,law.invention ,03 medical and health sciences ,follicles ,0302 clinical medicine ,Immune system ,Antigens, CD ,law ,Internal medicine ,Follicular phase ,medicine ,Animals ,Cytotoxic T cell ,Inflammation ,B-Lymphocytes ,Original Paper ,B cells ,Germinal center ,Forkhead Transcription Factors ,Cell Biology ,Germinal Center ,Macaca mulatta ,Lymphocyte Activation Gene 3 Protein ,Original Papers ,Immunity, Humoral ,030104 developmental biology ,Endocrinology ,medicine.anatomical_structure ,Suppressor ,Lymph Nodes ,Steady state (chemistry) ,Tfh cells ,030217 neurology & neurosurgery ,Granulocytes - Abstract
Age‐related reductions in vaccine‐induced B cells in aging indicate that germinal centers (GCs), the anatomical site where the development of humoral responses takes place, may lose efficacy with age. We have investigated the baseline follicular and GC composition in nonhuman primates (NHPs) with respect to their age. There was a marked reduction in follicular area in old animals. We found significantly lower normalized numbers of follicular PD1hi CD4 T (Tfh) and proliferating (Ki67hi) GC B cells with aging, a profile associated with significantly higher numbers of potential follicular suppressor FoxP3hiLag3hi CD4 T cells. Furthermore, a positive correlation was found between Tfh and follicular CD8 T cells (fCD8) only in young animals. Despite the increased levels of circulating preinflammatory factors in aging, young animals had higher numbers of monocytes and granulocytes in the follicles, a profile negatively associated with numbers of Tfh cells. Multiple regression analysis showed an altered association between GC B cells and other GC immune cell populations in old animals suggesting a differential mechanistic regulation of GC activity in aging. Our data demonstrate defective baseline GC composition in old NHPs and provide an immunological base for further understanding the adaptive humoral responses with respect to aging., Steady‐state germinal center immune reactivity is compromised in aged NHPs. This loss of reactivity is characterized by changes in many GC associated cell populations including Tfh, B cells, and follicular Tregs.
- Published
- 2019
41. Strong Th1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy
- Author
-
Traci Legere, Richard Green, James R. Bowen, Courtney Wilkins, Lynette S. Chea, Sunil Kannanganat, Tianwei Yu, Vijayakumar Velu, Jean Chang, Michelle A. Lifton, Venkateswarlu Chamcha, Sampa Santra, Pradeep B. J. Reddy, Cynthia A. Derdeyn, Pamela A. Kozlowski, Francois Villinger, Guido Silvestri, Eric Hunter, Rama Rao Amara, Sailaja Gangadhara, Lakshmi Chennareddi, Mehul S. Suthar, G. Lynn Law, and Michael Gale
- Subjects
Male ,Modified vaccinia Ankara ,Receptors, CCR5 ,Colon ,Simian Acquired Immunodeficiency Syndrome ,Priming (immunology) ,CD8-Positive T-Lymphocytes ,medicine.disease_cause ,Antibodies, Viral ,Article ,Interferon-gamma ,Immunity ,medicine ,Cytotoxic T cell ,Animals ,Lymphocyte Count ,HIV vaccine ,Mucous Membrane ,biology ,Gene Expression Profiling ,Vaccination ,SAIDS Vaccines ,General Medicine ,T-Lymphocytes, Helper-Inducer ,Simian immunodeficiency virus ,Virology ,Macaca mulatta ,Treatment Outcome ,Antibody Formation ,Vagina ,biology.protein ,Female ,Simian Immunodeficiency Virus ,Antibody - Abstract
Activated CD4 T cells are a major target of HIV infection. Results from the STEP HIV vaccine trial highlighted a potential role for total activated CD4 T cells in promoting HIV acquisition. However, the influence of vaccine insert-specific CD4 T cell responses on HIV acquisition is not known. Here, using the data obtained from four macaque studies, we show that the DNA prime/modified vaccinia Ankara boost vaccine induced interferon γ (IFNγ+) CD4 T cells [T helper 1 (TH1) cells] rapidly migrate to multiple tissues including colon, cervix, and vaginal mucosa. These mucosal TH1 cells persisted at higher frequencies and expressed higher density of CCR5, a viral coreceptor, compared to cells in blood. After intravaginal or intrarectal simian immunodeficiency virus (SIV)/simian-human immunodeficiency virus (SHIV) challenges, strong vaccine protection was evident only in animals that had lower frequencies of vaccine-specific TH1 cells but not in animals that had higher frequencies of TH1 cells, despite comparable vaccine-induced humoral and CD8 T cell immunity in both groups. An RNA transcriptome signature in blood at 7 days after priming immunization from one study was associated with induction of fewer TH1-type CD4 cells and enhanced protection. These results demonstrate that high and persisting frequencies of HIV vaccine-induced TH1-biased CD4 T cells in the intestinal and genital mucosa can mitigate beneficial effects of protective antibodies and CD8 T cells, highlighting a critical role of priming immunization and vaccine adjuvants in modulating HIV vaccine efficacy.
- Published
- 2019
42. Aerosol Delivery of Synthetic mRNA to Vaginal Mucosa Leads to Durable Expression of Broadly Neutralizing Antibodies against HIV
- Author
-
Jean M. Feugang, Amelia R. Woolums, Emmeline L. Blanchard, Alicia K. Olivier, Heath H King, Daryll Vanover, Peng Xiao, Pooja M. Tiwari, Peres Ramos Badial, Chiara Zurla, Francois Villinger, Philip J. Santangelo, Mariluz Araínga, Hannah E. Peck, Seong Bin Park, Merrilee Thoresen, and Kevin E. Lindsay
- Subjects
Human immunodeficiency virus (HIV) ,Simian Acquired Immunodeficiency Syndrome ,Fluorescent Antibody Technique ,Gene Expression ,HIV Infections ,HIV Antibodies ,medicine.disease_cause ,chemistry.chemical_compound ,Aerosol delivery ,Mice ,0302 clinical medicine ,Drug Discovery ,Chlorocebus aethiops ,Neutralizing antibody ,AIDS Vaccines ,0303 health sciences ,biology ,Vaginal mucosa ,animal models ,Titer ,SHIV ,intravaginal delivery ,030220 oncology & carcinogenesis ,synthetic mRNA ,Vagina ,Molecular Medicine ,Female ,Simian Immunodeficiency Virus ,Original Article ,Antibody ,PET/CT ,Glycosylphosphatidylinositol ,mRNA therapeutics ,03 medical and health sciences ,Neutralization Tests ,Genetics ,medicine ,Animals ,RNA, Messenger ,Molecular Biology ,Vero Cells ,030304 developmental biology ,Pharmacology ,Aerosols ,Messenger RNA ,Mucous Membrane ,Sheep ,business.industry ,HIV ,Virology ,chemistry ,biology.protein ,HIV-1 ,aerosol delivery ,business ,Broadly Neutralizing Antibodies - Abstract
There is a clear need for low-cost, self-applied, long-lasting approaches to prevent human immunodeficiency virus (HIV) infection in both men and women, even with the advent of pre-exposure prophylaxis (PrEP). Broadly neutralizing antibodies represent an option to improve HIV prophylaxis, but intravenous delivery, cold-chain stability requirements, low cervicovaginal concentrations, and cost may preclude their use. Here, we present an approach to express the anti-GP120 broadly neutralizing antibody PGT121 in the primary site of inoculation, the female reproductive tract, using synthetic mRNA. Expression is achieved through aerosol delivery of unformulated mRNA in water. We demonstrated high levels of antibody expression for over 28 days with a single mRNA administration in the reproductive tract of sheep. In rhesus macaques, neutralizing antibody titers in secretions developed within 4 h and simian-HIV (SHIV) infection of ex vivo explants was prevented. Persistence of PGT121 in vaginal secretions and epithelium was achieved through the incorporation of a glycosylphosphatidylinositol (GPI) anchor into the heavy chain of the antibody. Overall, we present a new paradigm to deliver neutralizing antibodies to the female reproductive tract for the prevention of HIV infections., Graphical Abstract, Santangelo and colleagues report on the aerosol delivery of synthetic mRNAs, diluted in water, to the cervicovaginal epithelium, which expresses membrane-anchored broadly neutralizing antibodies against HIV. In two large animal models, anchored PGT121 was widely dispersed in the reproductive tract and was protective against a SHIV explant challenge.
- Published
- 2019
43. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques
- Author
-
Paul Spearman, Jaang-Jiun Wang, Francois Villinger, Lingmei Ding, Peng Xiao, Xuemin Chen, Karnail Singh, and Bishal Marasini
- Subjects
Male ,Modified vaccinia Ankara ,viruses ,Immunology ,medicine.disease_cause ,Antibodies, Viral ,Vaccines, Attenuated ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Virus-like particle ,Viral Envelope Proteins ,Immunity ,Virology ,Vaccines and Antiviral Agents ,medicine ,Animals ,030212 general & internal medicine ,Vaccines, Virus-Like Particle ,Ebola Vaccines ,030304 developmental biology ,Glycoproteins ,0303 health sciences ,Ebola virus ,biology ,Ebola vaccine ,Vaccination ,virus diseases ,Viral Vaccines ,Hemorrhagic Fever, Ebola ,biology.organism_classification ,Ebolavirus ,Antibodies, Neutralizing ,Macaca mulatta ,Bundibugyo virus ,Africa, Western ,Disease Models, Animal ,Vesicular stomatitis virus ,Insect Science ,Female ,Immunization - Abstract
The 2013–2016 Ebola outbreak in West Africa led to accelerated efforts to develop vaccines against these highly virulent viruses. A live, recombinant vesicular stomatitis virus-based vaccine has been deployed in outbreak settings and appears highly effective. Vaccines based on replication-deficient adenovirus vectors either alone or in combination with a multivalent modified vaccinia Ankara (MVA) Ebola vaccine also appear promising and are progressing in clinical evaluation. However, the ability of current live vector-based approaches to protect against multiple pathogenic species of Ebola is not yet established, and eliciting durable responses may require additional booster vaccinations. Here, we report the development of a bivalent, spherical Ebola virus-like particle (VLP) vaccine that incorporates glycoproteins (GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus (SUDV) and is designed to extend the breadth of immunity beyond EBOV. Immunization of rabbits with bivalent Ebola VLPs produced antibodies that neutralized all four pathogenic species of Ebola viruses and elicited antibody-dependent cell-mediated cytotoxicity (ADCC) responses against EBOV and SUDV. Vaccination of rhesus macaques with bivalent VLPs generated strong humoral immune responses, including high titers of binding, as well as neutralizing antibodies and ADCC responses. VLP vaccination led to a significant increase in the frequency of Ebola GP-specific CD4 and CD8 T cell responses. These results demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and cellular immune responses against pathogenic Ebola viruses and support further evaluation of this approach as a potential addition to Ebola vaccine development efforts. IMPORTANCE Ebola outbreaks result in significant morbidity and mortality in affected countries. Although several leading candidate Ebola vaccines have been developed and advanced in clinical testing, additional vaccine candidates may be needed to provide protection against different Ebola species and to extend the durability of protection. A novel approach demonstrated here is to express two genetically diverse glycoproteins on a spherical core, generating a vaccine that can broaden immune responses against known pathogenic Ebola viruses. This approach provides a new method to broaden and potentially extend protective immune responses against Ebola viruses.
- Published
- 2019
44. Age associated microbiome modulation and its association with systemic inflammation in a Rhesus Macaque Model
- Author
-
Francois Villinger, Suresh Pallikkuth, Roberto Mendez, Tirupataiah Sirupangi, Rajendra Pahwa, Savita Pahwa, Santanu Banerjee, Kyle Russell, and Daniel Kvistad
- Subjects
0303 health sciences ,biology ,medicine.medical_treatment ,Inflammation ,Systemic inflammation ,biology.organism_classification ,03 medical and health sciences ,Rhesus macaque ,0302 clinical medicine ,Cytokine ,Metabolomics ,Immune system ,030220 oncology & carcinogenesis ,Immunology ,medicine ,Metabolome ,Microbiome ,medicine.symptom ,030304 developmental biology - Abstract
BackgroundAs the individual ages, the immune system decreases in activity while chronic systemic inflammation increases. The microbiome is also affected by age, decreasing in beneficial microbes while increasing in pathogenic, inflammation inducing microbes with corresponding changes in their metabolic profile. While aging is known to affect both, links between the two have been hard to uncover.MethodsFour young (age 3-6 years) and 12 old (age>18 years) Rhesus macaques were recruited for the study. PBMCs and plasma were collected to investigate immune cell subsets by flow cytometry and plasma cytokines by bead based multiplex cytokine analysis respectively. Stool samples were collected by ileal loop for microbiome analysis by shotgun metagenomics and serum, gut microbial lysate and microbe-free fecal extract was used to determine metabolomics by mass-spectrometry.ResultsOur aging NHP model recaptured many of the features of the age-associated immune alterations, with increased inflammation and alterations in immune cells subsets with lower number of CD4 T cells and a trend of age associated alterations in maturation subsets in older animals with lower naïve and higher central memory CD4 T cells. Older animals showed a significantly different microbiome from young animals with lower abundance of Firmicutes and higher Archaeal and Proteobacterial species. Correlation analysis showed a link between microbes in older animals with systemic inflammation. Analysis of metabolites in the serum and feces showed significant differences between specific metabolites between young and older animals that can influence age-associated morbidities.ConclusionThese data support the age associated alterations in microbiome profile and its association with persistent systemic inflammation and metabolome changes. Further mechanistic studies are needed to understand the relationship between inflammation and microbiome. Nevertheless, this NHP model recapitulates human age associated changes in immune, inflammatory and microbiome profiles and can be useful for designing future studies targeting microbiome modulations in aging.
- Published
- 2019
- Full Text
- View/download PDF
45. Early treatment of SIV+ macaques with an α4β7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection
- Author
-
Anthony S. Fauci, Katija Jelicic, Kenneth A. Rogers, James Arthos, Claudia Cicala, Francois Villinger, Jung Joo Hong, Aftab A. Ansari, Siddappa N. Byrareddy, Sanjeev Gumber, Philip J. Santangelo, Kristina Ortiz, Kevin E. Lindsay, Chiara Zurla, and Dawn M. Little
- Subjects
0301 basic medicine ,medicine.drug_class ,Immunology ,Spleen ,Biology ,Monoclonal antibody ,Clonal deletion ,Virus ,Pathogenesis ,03 medical and health sciences ,030104 developmental biology ,medicine.anatomical_structure ,Immune system ,medicine ,biology.protein ,Immunology and Allergy ,Antibody ,Viral load - Abstract
Integrin α4β7 mediates the trafficking of leukocytes, including CD4+ T cells, to lymphoid tissues in the gut. Virus mediated damage to the gut is implicated in HIV and SIV mediated chronic immune activation and leads to irreversible damage to the immune system. We employed an immuno-PET/CT imaging technique to evaluate the impact of an anti-integrin α4β7 mAb alone or in combination with ART, on the distribution of both SIV infected cells and CD4+ cells in rhesus macaques infected with SIV. We determined that α4β7 mAb reduced viral antigen in an array of tissues of the lung, spleen, axillary, and inguinal lymph nodes. These sites are not directly linked to α4β7 mediated homing; however, the most pronounced reduction in viral load was observed in the colon. Despite this reduction, α4β7 mAb treatment did not prevent an apparent depletion of CD4+ T cells in gut in the acute phase of infection that is characteristic of HIV/SIV infection. However, α4β7 mAb appeared to facilitate the preservation or restoration of CD4+ T cells in gut tissues at later stages of infection. Since damage to the gut is believed to play a central role in HIV pathogenesis, these results support further evaluation of α4β7 antagonists in the study and treatment of HIV disease.
- Published
- 2018
46. The Role of Integrin α4β7 in HIV Pathogenesis and Treatment
- Author
-
Francois Villinger, James Arthos, Claudia Cicala, Aftab A. Ansari, Siddappa N. Byrareddy, Philip J. Santangelo, Fatima Nawaz, and Anthony S. Fauci
- Subjects
0301 basic medicine ,Integrins ,HIV Pathogenesis and Treatment (AL Landay and N Utay, Section Editors) ,medicine.drug_class ,Gastrointestinal Diseases ,HIV Infections ,HIV/SIV ,Monoclonal antibody ,Antibodies, Monoclonal, Humanized ,Inflammatory bowel disease ,Vedolizumab ,Pathogenesis ,03 medical and health sciences ,Immune system ,Gastrointestinal Agents ,Virology ,medicine ,GALT ,Animals ,Humans ,business.industry ,medicine.disease ,Mucosal transmission ,Antiretroviral therapy ,030104 developmental biology ,Infectious Diseases ,Lymphatic system ,Viral replication ,Immunology ,Integrin α4β7 ,business ,Homing (hematopoietic) ,medicine.drug - Abstract
Purpose of Review Acute HIV infection is characterized by high-level viral replication throughout the body’s lymphoid system, particularly in gut-associated lymphoid tissues resulting in damage to structural components of gut tissue. This damage is irreversible and believed to contribute to the development of immune deficiencies. Antiretroviral therapy (ART) does not restore gut structure and function. Studies in macaques point to an alternative treatment strategy that may ameliorate gut damage. Integrin α4β7 mediates the homing of lymphocytes to gut tissues. Vedolizumab, a monoclonal antibody (mAb) antagonist of α4β7, has demonstrated efficacy and has been approved for the treatment of inflammatory bowel disease in humans. Here, we describe our current knowledge, and the gaps in our understanding, of the role of α4β7 in HIV pathogenesis and treatment. Recent Findings When administered to macaques prior to infection, a nonhuman primate analogue of vedolizumab prevents transmission of SIV. In combination with ART, this mAb facilitates durable virologic control following treatment interruption. Summary Targeting α4β7 represents a novel therapeutic approach to prevent and treat HIV infection.
- Published
- 2018
47. Localization of infection in neonatal rhesus macaques after oral viral challenge
- Author
-
Thomas J. Hope, Amanda Strickland, Mariluz Araínga, Samir K. Lakhashe, Edward J. Allen, Yanique Thomas, Sandeep Gupta, Kenneth A. Rogers, Francois Villinger, Meegan R. Anderson, Ramon Lorenzo-Redondo, Ruth M. Ruprecht, Michael D. McRaven, Viraj Kulkarni, Roslyn A. Taylor, Edgar Matias, and Ann M. Carias
- Subjects
RNA viruses ,Bacterial Diseases ,T-Lymphocytes ,viruses ,Simian Acquired Immunodeficiency Syndrome ,HIV Infections ,Pathology and Laboratory Medicine ,Virions ,Diagnostic Radiology ,White Blood Cells ,Medical Conditions ,Immunodeficiency Viruses ,Animal Cells ,Caries ,Positron Emission Tomography Computed Tomography ,Medicine and Health Sciences ,Medicine ,Gastrointestinal Infections ,Large intestine ,Biology (General) ,Tomography ,Gastrointestinal tract ,education.field_of_study ,biology ,T Cells ,Transmission (medicine) ,Radiology and Imaging ,Viral Load ,Tonsils ,Rhesus macaque ,Infectious Diseases ,medicine.anatomical_structure ,Medical Microbiology ,In utero ,Viral Pathogens ,Viruses ,Small Intestine ,Simian Immunodeficiency Virus ,Pathogens ,Cellular Types ,Anatomy ,Research Article ,Imaging Techniques ,QH301-705.5 ,Immune Cells ,Immunology ,Population ,Neuroimaging ,Gastroenterology and Hepatology ,Viral Structure ,Research and Analysis Methods ,Microbiology ,Virus ,Viral vector ,Throat ,Immune system ,Diagnostic Medicine ,Virology ,Retroviruses ,Genetics ,Animals ,Humans ,education ,Microbial Pathogens ,Molecular Biology ,Blood Cells ,business.industry ,Lentivirus ,Organisms ,Biology and Life Sciences ,HIV ,Cell Biology ,RC581-607 ,biology.organism_classification ,Macaca mulatta ,Small intestine ,Gastrointestinal Tract ,Animals, Newborn ,Copper Radioisotopes ,Viral replication ,HIV-1 ,Parasitology ,Immunologic diseases. Allergy ,business ,Digestive System ,Neck ,Positron Emission Tomography ,Neuroscience - Abstract
Vertical transmission of human immunodeficiency virus (HIV) can occur in utero, during delivery, and through breastfeeding. We utilized Positron Emission Tomography (PET) imaging coupled with fluorescent microscopy of 64Cu-labeled photoactivatable-GFP-HIV (PA-GFP-BaL) to determine how HIV virions distribute and localize in neonatal rhesus macaques two and four hours after oral viral challenge. Our results show that by four hours after oral viral exposure, HIV virions localize to and penetrate the rectal mucosa. We also used a dual viral challenge with a non-replicative viral vector and a replication competent SHIV-1157ipd3N4 to examine viral transduction and dissemination at 96 hours. Our data show that while SHIV-1157ipd3N4 infection can be found in the oral cavity and upper gastrointestinal (GI) tract, the small and large intestine contained the largest number of infected cells. Moreover, we found that T cells were the biggest population of infected immune cells. Thus, thanks to these novel technologies, we are able to visualize and delineate of viral distribution and infection throughout the entire neonatal GI tract during acute viral infection., Author summary Approximately 1.8 million children are currently living with human immunodeficiency virus (HIV). While mother-to-child HIV transmission can occur in utero and during delivery, it most commonly occurs through breastfeeding, creating the need to understand how the virus moves throughout the body and infects the infant once breast milk is consumed. Here, we used multiple imaging techniques and PCR to determine how HIV distributes throughout the gastrointestinal tract after oral viral exposure and in which tissues and cell types become acutely infected. We found that HIV rapidly spreads throughout and penetrates the entire gastrointestinal tract as early as four hours after exposure. We also found that the intestine contained the largest number of infected cells at 96 hours and that most cells infected were T cells. Our study shows that these imaging technologies allow for the examination of viral distribution and infection in a rhesus macaque model.
- Published
- 2021
48. Early initiation of antiretroviral treatment postSIV infection does not resolve lymphoid tissue activation
- Author
-
Jung Joo Hong, Kyu-Tae Chang, Siddappa N. Byrareddy, Francois Villinger, Sanjeev Gumber, Aftab A Ansari, Eduardo Lani Volpe da Silveira, and Praveen K. Amancha
- Subjects
0301 basic medicine ,Sustained Virologic Response ,Biopsy ,Immunology ,Simian Acquired Immunodeficiency Syndrome ,Biology ,Lymphocyte Activation ,medicine.disease_cause ,Article ,03 medical and health sciences ,Follicular phase ,Secondary Prevention ,medicine ,Animals ,Immunology and Allergy ,Lymph node ,medicine.diagnostic_test ,Germinal center ,RNA ,Simian immunodeficiency virus ,Macaca mulatta ,Virology ,030104 developmental biology ,Infectious Diseases ,Lymphatic system ,medicine.anatomical_structure ,Anti-Retroviral Agents ,Simian Immunodeficiency Virus ,Lymph Nodes ,Lymph - Abstract
Objective Germinal center resident follicular helper T (TFH) cells in lymphoid follicles are a potential sanctuary for HIV/simian immunodeficiency virus (SIV) replication. But the dynamics of germinal centers upon early initiation of antiretroviral therapy (ART) and their potential role in the formation of viral sanctuaries post-SIV infection are not fully understood. Design Sequential lymph node biopsies (n = 10) were collected from SIVmac239-infected rhesus macaques before infection, at 5 weeks postinfection/pre-ART, 6 and 12 weeks following ART initiation. These tissues and cells were analyzed for frequencies of TFH cells and assignment of germinal center scores. Results Modest but significant increases in TFH cells and hyperplastic follicles with large germinal centers were noted during the acute phase of SIV infection (week 5/pre-ART). However, 6 weeks after ART initiation, substantial increases in germinal center TFH cells, germinal center B cells, hyperplastic follicles with large germinal centers, and abundant local IL-21 production were observed, whereas levels of SIV RNA and DNA of lymph nodes had decreased to barely detectable values along with barely detectable levels of SIV antibody-producing cells. An additional 6 weeks of ART did not appreciably decrease germinal center TFH or germinal center scores. Conclusion Thus, although early ART rapidly controls SIV replication, it does not regulate early lymphoid activation, which may contribute to the seeding and magnitude of viral reservoirs.
- Published
- 2017
49. Immune Cell Dynamics in Rhesus Macaques Infected with a Brazilian Strain of Zika Virus
- Author
-
Siddappa N. Byrareddy, Mauro M. Teixeira, Eduardo Lani Volpe da Silveira, Francois Villinger, Peng Xiao, Shawna M. Woollard, Sanjeev Gumber, Praveen K. Amancha, and Kenneth A. Rogers
- Subjects
0301 basic medicine ,T-Lymphocytes ,T cell ,Immunology ,Viremia ,Biology ,Antibodies, Viral ,Article ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Semen ,medicine ,Animals ,Immunology and Allergy ,B-Lymphocytes ,Zika Virus Infection ,Germinal center ,Dendritic Cells ,Zika Virus ,Dendritic cell ,Viral Load ,medicine.disease ,Macaca mulatta ,Virology ,Killer Cells, Natural ,Disease Models, Animal ,Kinetics ,030104 developmental biology ,medicine.anatomical_structure ,Lymphatic system ,030220 oncology & carcinogenesis ,biology.protein ,Lymph Nodes ,Antibody ,Viral load ,Brazil - Abstract
Zika virus (ZIKV) is a mosquito-borne and sexually transmitted flavivirus that is associated with fetal CNS-damaging malformations during pregnancy in humans. This study documents the viral kinetics and immune responses in rhesus macaques infected with a clinical ZIKV Brazilian isolate. We evaluated the viral kinetics and immune responses induced after an i.v. infection with a Brazilian ZIKV clinical isolate (HS-2015-BA-01) in rhesus macaques for up to 142 d. ZIKV-specific Ab-secreting cells, germinal center reactions, and monocyte, dendritic cell, NK, and T cell frequencies were monitored. ZIKV loads were readily detected in plasma (until day 5 or 7), semen and urine (until days 7 and 14), and saliva (until day 42), but the viremia was rapidly controlled. No detectable clinical manifestations were observed. However, lymph node hyperplasia was clearly visible postviremia but was associated with low frequencies of ZIKV-specific Ab-secreting cells in lymph nodes and bone marrow, correlating with low Ab titers. CD14+/CD16− monocytes and myeloid CD11chi dendritic cells decreased in blood, whereas NK and T cell numbers were only marginally altered during the course of the study. ZIKV infection caused a significant lymphoid tissue activation but limited induction of ZIKV-specific B cells, suggesting that these parameters need to be considered for ZIKV vaccine design.
- Published
- 2017
50. Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques
- Author
-
Pramod N. Nehete, Kathryn A. Shelton, Guojun Yang, Stephanie S. Anguiano-Zarate, Ann J. Hessell, Philip Barnette, Michael A. Barry, William E. Matchett, Stephanie Dorta-Estremera, Francois Villinger, Peng Xiao, K. Jagannadha Sastry, Bharti P. Nehete, Siddappa N. Byrareddy, and Nancy L. Haigwood
- Subjects
animal diseases ,Immunology ,HIV Infections ,chemical and pharmacologic phenomena ,Biology ,Antibodies, Viral ,Injections, Intramuscular ,Microbiology ,Virus ,Adenoviridae ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Virology ,Vaccines and Antiviral Agents ,Animals ,030212 general & internal medicine ,Immunity, Mucosal ,Administration, Intranasal ,030304 developmental biology ,AIDS Vaccines ,Antibody-dependent cell-mediated cytotoxicity ,0303 health sciences ,Vaccination ,SAIDS Vaccines ,Antibody titer ,Gene Products, env ,T-Lymphocytes, Helper-Inducer ,Viral Load ,biochemical phenomena, metabolism, and nutrition ,Macaca mulatta ,Immunity, Innate ,Immunization ,Insect Science ,HIV-1 ,biology.protein ,Simian Immunodeficiency Virus ,Antibody ,Viral load - Abstract
Most human immunodeficiency virus type 1 (HIV-1) infections begin at mucosal surfaces. Providing a barrier of protection at these may assist in combating the earliest events in infection. Systemic immunization by intramuscular (i.m.) injection can drive mucosal immune responses, but there are data suggesting that mucosal immunization can better educate these mucosal immune responses. To test this, rhesus macaques were immunized with replicating single-cycle adenovirus (SC-Ad) vaccines expressing clade B HIV-1 gp160 by the intranasal (i.n.) and i.m. routes to compare mucosal and systemic routes of vaccination. SC-Ad vaccines generated significant circulating antibody titers against Env after a single i.m. immunization. Switching the route of second immunization with the same SC-Ad serotype allowed a significant boost in these antibody levels. When these animals were boosted with envelope protein, envelope-binding antibodies were amplified 100-fold, but qualitatively different immune responses were generated. Animals immunized by only the i.m. route had high peripheral T follicular helper (pTfh) cell counts in blood but low Tfh cell counts in lymph nodes. Conversely, animals immunized by the i.n. route had high Tfh cell counts in lymph nodes but low pTfh cell counts in the blood. Animals immunized by only the i.m. route had lower antibody-dependent cellular cytotoxicity (ADCC) antibody activity, whereas animals immunized by the mucosal i.n. route had higher ADCC antibody activity. When these Env-immunized animals were challenged rectally with simian-human immunodeficiency virus (SHIV) strain SF162P3 (SHIV(SF162P3)), they all became infected. However, mucosally SC-Ad-immunized animals had lower viral loads in their gastrointestinal tracts. These data suggest that there may be benefits in educating the immune system at mucosal sites during HIV vaccination. IMPORTANCE HIV-1 infections usually start at a mucosal surface after sexual contact. Creating a barrier of protection at these mucosal sites may be a good strategy for to protect against HIV-1 infections. While HIV-1 enters at mucosa, most vaccines are not delivered here. Most are instead injected into the muscle, a site well distant and functionally different than mucosal tissues. This study tested if delivering HIV vaccines at mucosa or in the muscle makes a difference in the quality, quantity, and location of immune responses against the virus. These data suggest that there are indeed advantages to educating the immune system at mucosal sites with an HIV-1 vaccine.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.